: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Liver Diseases

Free Subscription

Articles published in Hepatology
Retrieve available abstracts of 1239 articles:
HTML format

Single Articles

August 2024

Hepatology Highlights.
Hepatology. 2024;80:255-256.
PubMed

GARCIA-TSAO G, Kaplan DE
Reply: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
Hepatology. 2024;80:E36.
PubMed

RAMAN KP, Patch D
Tranexamic acid in variceal bleeding revisited.
Hepatology. 2024;80:257-259.
PubMed

JEPSEN P, West J, Kann AE, Kraglund F, et al
Risk of alcohol-associated liver disease in the offspring of parents with alcohol-associated liver disease: A nationwide cohort study.
Hepatology. 2024;80:418-427.
PubMed Abstract available

WANG Q, Bu Q, Pan B, Yin Y, et al
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
Hepatology. 2024;80:E24-E25.
PubMed

YANG D, Tian T, Li X, Zhang B, et al
ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.
Hepatology. 2024;80:312-329.
PubMed Abstract available

HLADY RA, Robertson KD
Epigenetic memory of environmental exposures as a mediator of liver disease.
Hepatology. 2024;80:451-464.
PubMed Abstract available

July 2024

JEONG JM, Choi SE, Shim YR, Kim HH, et al
CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression.
Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001021.
PubMed Abstract available

CELSA C, Cabibbo G, Fulgenzi CAM, Battaglia S, et al
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026.
PubMed Abstract available

Diagnosis and Management of Hepatocellular Carcinoma.
Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001010.
PubMed

ZHANG L, Xie P, Li M, Zhang X, et al
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
PubMed Abstract available

HUANG Y, Yu F, Ding Y, Zhang H, et al
Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.
Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000000998.
PubMed Abstract available

HOOVER JM
Letter to the Editor: Utilization of beta blockers in patients with portal hypertension and peripheral artery disease.
Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001008.
PubMed

KENT D, Ng SS, Syanda AM, Khoshkenar P, et al
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Hepatology. 2024 Jul 2. doi: 10.1097/HEP.0000000000000969.
PubMed Abstract available

Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
Hepatology. 2024;80:E23.
PubMed

Hepatology Highlights.
Hepatology. 2024;80:1-2.
PubMed

LAINE L, Barkun AN, Leontiadis GI
Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
Hepatology. 2024;80:E15-E16.
PubMed

KRAWCZYK M, Lammert F
Letter to the Editor: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
Hepatology. 2024;80:E11-E12.
PubMed

RINELLA ME, Lazarus JV, Newsome PN
Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
Hepatology. 2024;80:E13-E14.
PubMed

MA J, Liangpunsakul S
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
Hepatology. 2024;80:14-17.
PubMed

DAVENPORT M
Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
Hepatology. 2024;80:18-19.
PubMed

WOLTERS F, Oude Elferink RPJ, Beuers U
PPARalpha, PPARdelta, or both-that is the question!
Hepatology. 2024;80:8-10.
PubMed

KOSHIOL J, Krawczyk M
enHanCCing knowledge of genetic factors in primary liver tumor.
Hepatology. 2024;80:11-13.
PubMed

NEIL DAH, Smith ML, Minervini M, Demetris AJ, et al
Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
Hepatology. 2024;80:E6-E7.
PubMed

CAO H, Gu J
Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
Hepatology. 2024;80:E4-E5.
PubMed

ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
Hepatology. 2024;80:163-172.
PubMed Abstract available

FLORIS A, Chandla S, Lim Y, Barbier-Torres L, et al
Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.
Hepatology. 2024;80:102-118.
PubMed Abstract available

LOPEZ-PASCUAL A
Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.
Hepatology. 2024;80:20-23.
PubMed

SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
Hepatology. 2024;80:119-135.
PubMed Abstract available

TONG Y, Wang F, Li S, Guo W, et al
Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
Hepatology. 2024;80:38-54.
PubMed Abstract available

SINGAL AK, Shah VH, Malhi H
Emerging targets for therapy in ALD: Lessons from NASH.
Hepatology. 2024;80:223-237.
PubMed Abstract available

Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
Hepatology. 2024;80:E21.
PubMed

PREMKUMAR M, Karvellas CJ, Kulkarni AV, Bhujade H, et al
Role of Point-of-Care ultrasound (POCUS) in clinical hepatology.
Hepatology. 2024 Jul 1. doi: 10.1097/HEP.0000000000000990.
PubMed Abstract available

June 2024

GAO D, Ping Yam JW
Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma.
Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000001000.
PubMed

PREMKUMAR M, Kulkarni A, Izzy M
'Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography'.
Hepatology. 2024 Jun 26. doi: 10.1097/HEP.0000000000000988.
PubMed

LUO X, Yu J
Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury.
Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000984.
PubMed

RATZIU V, Yilmaz Y, Lazas D, Friedman SL, et al
Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.
Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980.
PubMed Abstract available

KANG K, Wu Y
Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000945.
PubMed

LI J, Ma X, Xuan Q, Li Q, et al
Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
PubMed Abstract available

YANG M, Song X, Zhang F, Li M, et al
Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000979.
PubMed Abstract available

BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
PubMed

LIU Q, Zhang X, Qi J, Tian X, et al
Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for hepatocellular carcinoma.
Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000962.
PubMed Abstract available

Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
PubMed

HUANG L, Zou L
Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
PubMed

Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
Hepatology. 2024;79:E171-E172.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:1239-1240.
PubMed

LI Z, Zhang Y, Li Y, Lan J, et al
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
Hepatology. 2024;79:E169-E170.
PubMed

LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2024;79:E155-E156.
PubMed

CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2024;79:E153-E154.
PubMed

YEH JG, Newsome PN
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Hepatology. 2024;79:1255-1257.
PubMed

HANSEN BE, Vandriel SM, Vig P, Garner W, et al
Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
Hepatology. 2024;79:1279-1292.
PubMed Abstract available

ABDELMALEK MF, Rinella ME
Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
Hepatology. 2024;79:1252-1254.
PubMed

ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Hepatology. 2024;79:1401-1411.
PubMed Abstract available

ZHAO G, Ma Q, Yang H, Jiang H, et al
Base editing of the mutated TERT promoter inhibits liver tumor growth.
Hepatology. 2024;79:1310-1323.
PubMed Abstract available

SCHMIDT KA, Simonetto DA
The telomere tango: Liver disease in the genomic spotlight.
Hepatology. 2024;79:1249-1251.
PubMed

SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
Hepatology. 2024;79:1365-1380.
PubMed Abstract available

UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
Hepatology. 2024;79:1352-1364.
PubMed Abstract available

WANG A, Blackford AL, Behling C, Wilson LA, et al
Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
Hepatology. 2024;79:1381-1392.
PubMed Abstract available

JIN Y, Shou Y, Lei Q, Du C, et al
An entropy weight method to integrate big omics and mechanistically evaluate DILI.
Hepatology. 2024;79:1264-1278.
PubMed Abstract available

AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
Human liver organoids: From generation to applications.
Hepatology. 2024;79:1432-1451.
PubMed Abstract available

May 2024

MANTOVANI S, Mondelli MU
Platelets harness innate immunity to promote dissemination of hepatocellular carcinoma.
Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000946.
PubMed

GUO C, Liu Z, Zhang T
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
PubMed

MUSSO G, Pinach S, Mariano F, Saba F, et al
Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
PubMed Abstract available

MOORE MP, Wang X, Kennelly JP, Shi H, et al
Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
PubMed Abstract available

KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Hepatology. 2024;79:1212-1219.
PubMed Abstract available

NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
Hepatology. 2024;79:E130-E131.
PubMed

ZAHRAWI FM, Mehal WZ
Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
Hepatology. 2024;79:E129.
PubMed

STOCKDALE AJ, Degasperi E
HDV RNA and liver disease progression: What do we know?
Hepatology. 2024;79:983-985.
PubMed

DESERT R, Foucher F, Guillout M, Nieto N, et al
Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
Hepatology. 2024;79:E141-E143.
PubMed

WANG TC, Xiao YD, Zhou P
Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
Hepatology. 2024;79:E140.
PubMed

LIU H, Li H, Wang DX, Li T, et al
Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Hepatology. 2024;79:E144-E145.
PubMed

DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Hepatology. 2024;79:E146-E147.
PubMed

KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
Hepatology. 2024;79:1065-1074.
PubMed Abstract available

SQUIRES JE, Horslen SP
Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
Hepatology. 2024;79:970-972.
PubMed

DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Hepatology. 2024;79:1107-1116.
PubMed Abstract available

LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
Genetic landscape of pediatric acute liver failure of indeterminate origin.
Hepatology. 2024;79:1075-1087.
PubMed Abstract available

AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
Hepatology. 2024;79:1098-1106.
PubMed Abstract available

TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
Hepatology. 2024;79:1141-1157.
PubMed Abstract available

SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
Spatial metabolomics and its application in the liver.
Hepatology. 2024;79:1158-1179.
PubMed Abstract available

Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
Hepatology. 2024;79:E150-E151.
PubMed

April 2024

KUMAR M, Venishetty S
Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
PubMed

ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
PubMed Abstract available

LI X, Zhang Y, Li S, Shi J, et al
Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
PubMed Abstract available

CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
PubMed

LEE YT, Tseng HR, Yang JD
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
PubMed

GUO C, Liu Z, Fan H, Wang H, et al
Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
PubMed Abstract available

HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
PubMed Abstract available

PRZYBYSZEWSKI EM, Bhan I, Yarze JC
Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
PubMed

GARCIA-TSAO G, Kaplan DE
Reply: On the use of non-selective beta blockers in cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
PubMed

VOLK ML
Innovations in Healthcare Delivery for Patients with Cirrhosis.
Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
PubMed

MOGHE A, McGuire BM, Levy C
Acute hepatic porphyrias - a guide for Hepatologists.
Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
PubMed Abstract available

SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
PubMed Abstract available

LI J, Allen AM, Yin M
Reply: Comparing quantitative MRI technologies in steatotic liver disease.
Hepatology. 2024;79:E121-E122.
PubMed

ALKHOURI N, Harisinghani M
Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
Hepatology. 2024;79:E119-E120.
PubMed

FRANSES JW, Duda DG
Scirrhous HCC: Another 'omic thread in the HCC tapestry.
Hepatology. 2024;79:747-748.
PubMed

VOLKERT I, Fromme M, Schneider C, Candels L, et al
Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
Hepatology. 2024;79:898-911.
PubMed Abstract available

LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
Mechanisms of drug resistance in HCC.
Hepatology. 2024;79:926-940.
PubMed Abstract available

Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
Hepatology. 2024;79:E128.
PubMed

Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
Hepatology. 2024;79:E127.
PubMed

April 2024 Hepatology Highlights.
Hepatology. 2024;79:745-746.
PubMed

TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
PubMed Abstract available

TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
PubMed Abstract available

March 2024

Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
PubMed

DENG T, Chen G
Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
PubMed

CRUZ C, Prado CM, Gillis C, Martindale R, et al
Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
PubMed Abstract available

FENG X, Feng B, Zhou J, Yang J, et al
Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
PubMed Abstract available

GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
PubMed Abstract available

ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
PubMed Abstract available

CHEN Y, Deng X, Li Y, Han Y, et al
Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
PubMed Abstract available

CULLARO G, Allegretti AS, Fenton C, Ge J, et al
The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
PubMed Abstract available

WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
PubMed Abstract available

MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
PubMed Abstract available

STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
PubMed

STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
PubMed

STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
PubMed

ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
PubMed Abstract available

DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
PubMed Abstract available

MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
PubMed Abstract available

BU W, Sun X, Xue X, Geng S, et al
Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
PubMed Abstract available

MUNOZ AE, Rodger EG
Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
PubMed

SHARPTON S, Loomba R
Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
PubMed

GUO Q, Wang J, Wang G, Wang X, et al
Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
PubMed

BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
PubMed Abstract available

SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
PubMed Abstract available

AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
PubMed Abstract available

ROY A, Kajal K, Izzy M, Sihag BK, et al
Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
PubMed

KUMAR M, Venishetty S, Jindal A, Bihari C, et al
Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
PubMed Abstract available

Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
Hepatology. 2024;79:E105.
PubMed

HOOFNAGLE JH, Doo E
Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2024;79:E91-E92.
PubMed

LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2024;79:E93-E94.
PubMed

BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
Hepatology. 2024;79:E87-E88.
PubMed

LEVY C, Dickey AK, Anderson KE, Keel SB, et al
Reply: Contrasting effect of iron supplementation in protoporphyria.
Hepatology. 2024;79:E89-E90.
PubMed

NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
Hepatology. 2024;79:624-635.
PubMed Abstract available

WANG F, Chen L, Kong D, Zhang X, et al
Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
Hepatology. 2024;79:606-623.
PubMed Abstract available

LEE BP, Dodge JL, Terrault NA
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
Hepatology. 2024;79:666-673.
PubMed Abstract available

BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
Hepatology. 2024;79:551-559.
PubMed Abstract available

LEDENKO M, Antwi SO, Patel T
Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
Hepatology. 2024;79:575-588.
PubMed Abstract available

LEVY C, Dickey AK, Wang B, Thapar M, et al
Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
Hepatology. 2024;79:731-743.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:525-526.
PubMed

February 2024

WONG YJ, Teng M, Sim A, Thet HM, et al
Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
PubMed Abstract available

HASSAN MM, Li D, Han Y, Byun J, et al
Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
PubMed Abstract available

ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
PubMed Abstract available

PENG Z, Wei G, Huang P, Matta H, et al
ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
PubMed Abstract available

HE B, Huang Z, Qin S, Peng P, et al
Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
PubMed Abstract available

CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
PubMed Abstract available

PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
PubMed

PAPATHERODORIDIS G, Lampertico P
Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
PubMed

ZHU M, Liu Z, Chen S, Luo Z, et al
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
PubMed Abstract available

PARK JG, Roh PR, Kang MW, Cho SW, et al
Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
PubMed Abstract available

DONGELMANS E, Erler N, Adam R, Nadalin S, et al
Recent outcomes of liver transplantation for Budd Chiari Syndrome - a study of the European Liver Transplant Registry (ELTR) and affiliated centers.
Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000778.
PubMed Abstract available

AGRAWAL D, Ariga KK
Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
PubMed

ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
PubMed Abstract available

MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
PubMed

EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
PubMed Abstract available

RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
Hepatology. 2024;79:E16-E17.
PubMed

CUSI K, Younossi Z, Roden M
From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
Hepatology. 2024;79:E13-E15.
PubMed

BALAKRISHNAN M, Rehm J
A public health perspective on mitigating the global burden of chronic liver disease.
Hepatology. 2024;79:451-459.
PubMed Abstract available

KHALID M, Khan ZM, Sheraz Kahloon A
Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
Hepatology. 2024;79:E18-E19.
PubMed

KIM Y, Chang Y, Ryu S, Wild SH, et al
Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
Hepatology. 2024;79:E20-E21.
PubMed

BARR RG, Bolondi L
Contrast-enhanced US for HCC: Finally out from the waiting list?
Hepatology. 2024;79:267-268.
PubMed

LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
Hepatology. 2024;79:380-391.
PubMed Abstract available

HUANG H, Tsui YM, Ho DW, Chung CY, et al
LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
Hepatology. 2024;79:323-340.
PubMed Abstract available

LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
A global action agenda for turning the tide on fatty liver disease.
Hepatology. 2024;79:502-523.
PubMed Abstract available

MENG Z, Zhou L, Hong S, Qiu X, et al
Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
Hepatology. 2024;79:409-424.
PubMed Abstract available

SINHA S, Hassan N, Schwartz RE
Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
Hepatology. 2024;79:482-501.
PubMed Abstract available

Hepatology Highlights.
Hepatology. 2024;79:255-256.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:255-256.
PubMed

January 2024

Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
PubMed

WANG Y, Wang X, Bai B, Shaha A, et al
Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
PubMed Abstract available

XIA Y, Wang Y, Xiong Q, He J, et al
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
PubMed Abstract available

Hepatology highlights.
Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
PubMed

NAKAGAWA H, Lin A
The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
PubMed

NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
PubMed Abstract available

TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
PubMed Abstract available

Hepatology Highlights.
Hepatology. 2024;79:1-2.
PubMed

BARGELLINI I, Rimassa L, Masi G
SIRT and chemotherapy in unresectable iCCA: Ready to take off.
Hepatology. 2024;79:9-11.
PubMed

EMANUELE E, Minoretti P
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
Hepatology. 2024;79:E4.
PubMed

NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
Hepatology. 2024;79:E5-E6.
PubMed

ROWE IA
Prediction of outcomes in patients with acute variceal bleeding.
Hepatology. 2024;79:15-17.
PubMed

WANG CC, Cheng YM, Kao JH
Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
Hepatology. 2024;79:E7-E8.
PubMed

GARCIA-CRIADO A, Bruix J
Screening for liver cancer: The good, the bad, and the ugly.
Hepatology. 2024;79:12-14.
PubMed

CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Hepatology. 2024;79:39-48.
PubMed Abstract available

LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
Hepatology. 2024;79:224-250.
PubMed

Hepatology Highlights.
Hepatology. 2024;79:1-2.
PubMed

December 2023

HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
PubMed Abstract available

VAJRO P, Mandato C
Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
PubMed

JENG WJ, Chien RN, Liaw YF
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
PubMed

CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
PubMed

WIEGAND J, Franke A, Stein K, Trautwein C, et al
Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
PubMed

WATT KD, Khan MQ
Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
PubMed

CHEN J, Tu T, Cohen C, Wang S, et al
Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
PubMed

ZABRANSKY DJ, Yarchoan M, Ho WJ
Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
PubMed

LU T, Zhang J, Li H, Li G, et al
Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
PubMed

KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
PubMed Abstract available

RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
PubMed Abstract available

VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
PubMed Abstract available

SCHULZE RJ, Strom SC, Nyberg SL
From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
PubMed

YU S, Liu X, Xu Y, Pan L, et al
m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
PubMed Abstract available

YIN C, Zhang C, Wang Y, Liu G, et al
ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
PubMed Abstract available

CHAN FF, Yuen VW, Shen J, Chin DW, et al
Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
PubMed Abstract available

MALHI H, Brown RS Jr, Lim JK, Reau N, et al
Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
Hepatology. 2023;78:1680-1681.
PubMed

RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2023;78:1966-1986.
PubMed Abstract available

DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
Hepatology. 2023;78:1788-1799.
PubMed Abstract available

ABERG F
Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
Hepatology. 2023;78:E101-E102.
PubMed

RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
Hepatology. 2023;78:E103-E104.
PubMed

ZHANG X, Yip TC, Tse YK, Hui VW, et al
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
Hepatology. 2023;78:1816-1827.
PubMed Abstract available

GAO R, Li Y, Xu Z, Zhang F, et al
Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
Hepatology. 2023;78:1800-1815.
PubMed Abstract available

Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
Hepatology. 2023;78:E110.
PubMed

Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
Hepatology. 2023;78:E108.
PubMed

Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
Hepatology. 2023;78:E107.
PubMed

MAIWALL R, Piano S, Singh V, Caraceni P, et al
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
PubMed Abstract available

Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
Hepatology. 2023;78:1682-1683.
PubMed

November 2023

HU YX, Diao LT, Hou YR, Lv G, et al
PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
PubMed Abstract available

PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
PubMed Abstract available

MICHALOPOULOS GK
Hepatocytes of mice and men: Different regenerative signals?
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
PubMed

KE L, Rui Z, Fukai W, Yunzheng Z, et al
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
PubMed Abstract available

February 2024 Hepatology Highlights.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
PubMed

LIU N, Tian J, Steer CJ, Han Q, et al
MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
PubMed Abstract available

KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
PubMed

QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
PubMed

BRENNER DA
Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
PubMed Abstract available

SCHERR AL, Nader L, Xu K, Elssner C, et al
Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
PubMed Abstract available

D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
PubMed Abstract available

RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
Hepatology. 2023;78:E91-E92.
PubMed

ARIAS-LOSTE MT, Crespo J, Iruzubieta P
Letter to the Editor: Updated guidance on NAFLD screening.
Hepatology. 2023;78:E89-E90.
PubMed

SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
Hepatology. 2023;78:E87-E88.
PubMed

YANG Z, Ding WX
The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
Hepatology. 2023;78:1329-1331.
PubMed

LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
It is time to expand the fatty liver disease community of practice.
Hepatology. 2023;78:1325-1328.
PubMed

TILG H, Adolph TE, Tacke F
Therapeutic modulation of the liver immune microenvironment.
Hepatology. 2023;78:1581-1601.
PubMed Abstract available

NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
Hepatology. 2023;78:1337-1351.
PubMed Abstract available

WU Q, Pan C, Zhou Y, Wang S, et al
Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
Hepatology. 2023;78:1402-1417.
PubMed Abstract available

SONG Y, Wei J, Li R, Fu R, et al
Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
Hepatology. 2023;78:1433-1447.
PubMed Abstract available

CHIU YT, Husain A, Sze KM, Ho DW, et al
Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
Hepatology. 2023;78:1368-1383.
PubMed Abstract available

YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
Metabolic reprogramming and its clinical implication for liver cancer.
Hepatology. 2023;78:1602-1624.
PubMed Abstract available

LEE CM, Yoon EL, Kim M, Kang BK, et al
Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
PubMed Abstract available

BRAILLON A, Naudet F
Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
PubMed

October 2023

JENG WJ, Chien RN, Liaw YF
Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
PubMed

DENG R, Wang Z, Liu Y, Sun J, et al
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
PubMed

GRATACOS-GINES J, Lopez-Pelayo H, Pose E
Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
PubMed

SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
PubMed Abstract available

SONG Y, Ye T, Roberts LR, Larson NB, et al
Randomization in hepatology: A review of principles, opportunities, and challenges.
Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
PubMed Abstract available

KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
PubMed

YANG T, Qu X, Wang X, Xu D, et al
Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
PubMed Abstract available

CHANG CW, Chen YS, Huang CH, Lin CH, et al
A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
PubMed Abstract available

OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
PubMed Abstract available

CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
PubMed Abstract available

GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
PubMed Abstract available

DONGELMANS EJ, Sonneveld MJ, Janssen HLA
Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
PubMed

LIAW YF, Jeng WJ, Chien RN
Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
PubMed

Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
PubMed

VONADA A, Wakefield L, Martinez M, Harding CO, et al
Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
PubMed Abstract available

CHEN P, Dong Z, Zhu W, Chen J, et al
Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
PubMed Abstract available

MA S, Chew V
Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
PubMed

THIELE M, Johansen S, Israelsen M, Trebicka J, et al
Non-invasive assessment of hepatic decompensation.
Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
PubMed Abstract available

PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
PubMed Abstract available

XANTHAKOS S
Rising tide of NAFLD in youth: A warning bell and call to action.
Hepatology. 2023;78:1017-1019.
PubMed

ANTON A, Shalaby S, Hernandez-Gea V
Coagulation meets senescence in NASH!
Hepatology. 2023;78:1023-1025.
PubMed

YONEDA M, Nakajima A
The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
Hepatology. 2023;78:1020-1022.
PubMed

CHEN W, Sun Y, Chen S, Ge X, et al
Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
Hepatology. 2023;78:1118-1132.
PubMed Abstract available

LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
Hepatology. 2023;78:1200-1208.
PubMed Abstract available

KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
Hepatology. 2023;78:1032-1034.
PubMed

MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
Intermittent fasting-the future treatment in NASH patients?
Hepatology. 2023;78:1290-1305.
PubMed Abstract available

CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
Predicting liver-related events in NAFLD: A predictive model.
Hepatology. 2023;78:1240-1251.
PubMed Abstract available

SEIMIYA T, Otsuka M, Fujishiro M
Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
Hepatology. 2023;78:1009-1011.
PubMed

Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Hepatology. 2023;78:E85.
PubMed

STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
Future directions in acute liver failure.
Hepatology. 2023;78:1266-1289.
PubMed Abstract available

HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
Hepatology. 2023;78:1168-1181.
PubMed Abstract available

KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
Hepatology. 2023;78:1106-1117.
PubMed Abstract available

DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
Semaphorin 3C exacerbates liver fibrosis.
Hepatology. 2023;78:1092-1105.
PubMed Abstract available

September 2023

NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
PubMed Abstract available

LI M, Wang L, Cong L, Wong CC, et al
Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
PubMed Abstract available

RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
PubMed Abstract available

ZHAO X, Kotha S, Nayyar D, Ma X, et al
Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
PubMed Abstract available

FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
PubMed Abstract available

GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
PubMed Abstract available

WATT KD, Paul S, Khan MQ, Siddiqui M, et al
Obesity management for the hepatologist - what to do, how to do it and why.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
PubMed Abstract available

CHEN S, Liao C, Hu H, Liao J, et al
Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
PubMed Abstract available

MAESTRI E, Kedei N, Khatib S, Forgues M, et al
Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
PubMed Abstract available

ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
PubMed Abstract available

December 2023 Hepatology Highlights.
Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
PubMed

LAZARUS JV, Han H, Mark HE, Alqahtani SA, et al
The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories.
Hepatology. 2023;78:911-928.
PubMed Abstract available

AWAN MZUA, Patel T
Letter to the Editor: Dynamic risk profiling of HCC recurrence after curative intent liver resection.
Hepatology. 2023;78:E55.
PubMed

HUANG CH, Hsieh SY
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC.
Hepatology. 2023;78:706-708.
PubMed

YOU M, Gao Y, Fu J, Xie R, et al
Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC.
Hepatology. 2023;78:943-958.
PubMed Abstract available

LLORENTE C, Rungratanawanich W, Liangpunsakul S
Intestinal dendritic cells, gatekeepers preventing ethanol-induced liver disease.
Hepatology. 2023;78:697-701.
PubMed

UCHIDA T, Imamura M, Hayes CN, Suehiro Y, et al
HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice.
Hepatology. 2023;78:929-942.
PubMed Abstract available

GOIKOETXEA-USANDIZAGA N, Bravo M, Egia-Mendikute L, Abecia L, et al
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent.
Hepatology. 2023;78:878-895.
PubMed Abstract available

WONG C, Dash A, Fredrickson J, Lewin-Koh N, et al
Fibroblast growth factor receptor 1/Klothobeta agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial.
Hepatology. 2023;78:847-862.
PubMed Abstract available

LAM KH, Ma S
Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications.
Hepatology. 2023;78:991-1005.
PubMed Abstract available

WU T, Chen X, Xu K, Dai C, et al
LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
PubMed Abstract available

August 2023

SHIMADA S, Tanaka S
The chronicles of hepatocellular carcinoma classification: Subtyping, modeling and treatment.
Hepatology. 2023 Aug 30. doi: 10.1097/HEP.0000000000000588.
PubMed

GRATACOS-GINES J, Bruguera P, Perez-Guasch M, Lopez-Lazcano A, et al
Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis.
Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000570.
PubMed Abstract available

JENG WJ, Chien RN, Chen YC, Lin CL, et al
Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
PubMed Abstract available

CHIN A, Bastaich DR, Dahman B, Kaplan DE, et al
Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites.
Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000577.
PubMed Abstract available

GE J, Fontil V, Ackerman S, Pletcher MJ, et al
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
PubMed Abstract available

PEISELER M, Tacke F
Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
PubMed

November hepatology highlights.
Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000565.
PubMed

KOWALIK MA, Taguchi K, Serra M, Caddeo A, et al
Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes.
Hepatology. 2023 Aug 21. doi: 10.1097/HEP.0000000000000568.
PubMed Abstract available

LV Y, Bai W, Zhu X, Xue H, et al
Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding.
Hepatology. 2023 Aug 18. doi: 10.1097/HEP.0000000000000548.
PubMed Abstract available

TREBICKA J, Garcia-Tsao G
Controversies regarding albumin therapy in cirrhosis.
Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000521.
PubMed Abstract available

LI B, Li Y, Zhou H, Xu Y, et al
Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
Hepatology. 2023 Aug 7. doi: 10.1097/HEP.0000000000000553.
PubMed Abstract available

BOWLUS CL, Levy C
Optimizing treatment of primary biliary cholangitis: Is good, good enough?
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
PubMed

DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
PubMed Abstract available

HU Y, Li Z, He W, Wang X, et al
Letter to the Editor: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
Hepatology. 2023;78:E29-E30.
PubMed

VAN KLEEF LA, Sonneveld MJ, de Knegt RJ
Reply: Is there survival bias? The etiologic analysis for the negative association between fatty liver and mortality in the elderly populations.
Hepatology. 2023;78:E31-E32.
PubMed

RONOT M, Nahon P, Rimola J
Screening of liver cancer with abbreviated MRI.
Hepatology. 2023;78:670-686.
PubMed Abstract available

MCCONNELL MJ, Kostallari E, Ibrahim SH, Iwakiri Y, et al
The evolving role of liver sinusoidal endothelial cells in liver health and disease.
Hepatology. 2023;78:649-669.
PubMed Abstract available

AN J, Oh JH, Oh B, Oh YJ, et al
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient hepatocellular carcinoma.
Hepatology. 2023;78:452-467.
PubMed Abstract available

GUO X, Tan S, Wang T, Sun R, et al
NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity.
Hepatology. 2023;78:468-485.
PubMed Abstract available

August Hepatology Highlights.
Hepatology. 2023;78:369-370.
PubMed

July 2023

LI Y, Li B, Xiao X, Qian Q, et al
Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
PubMed Abstract available

SENZOLO M, Shalaby S, Grasso M, Vitale A, et al
Role of non-neoplastic portal vein thrombosis in the natural history of patients with cirrhosis and first diagnosis of hepatocellular carcinoma.
Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000538.
PubMed Abstract available

EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
PubMed Abstract available

NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).
Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000542.
PubMed Abstract available

October Hepatology Highlights.
Hepatology. 2023 Jul 24. doi: 10.1097/HEP.0000000000000543.
PubMed

MA X, Ding WX
Reply: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000541.
PubMed

HU X, Shen J, Wang T, Liu M, et al
Letter to the Editor: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitichondria and mitochondrial maladaptation.
Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000540.
PubMed

Retraction: Protein kinase a-dependent pSer675-beta-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis.
Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000486.
PubMed

GE J, Digitale JC, Pletcher MJ, Lai JC, et al
Reply: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000536.
PubMed

XIANG X, Hao Y, Cheng C, Hu H, et al
A TGF-beta-dominant chemo-resistant phenotype of hepatoblastoma associated with aflatoxin exposure in children.
Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000534.
PubMed Abstract available

HU Y, Li Z, He W, Wang X, et al
Letter to the Editor: What is the actual role of decompensated cirrhosis in the breakthrough SARS-CoV-2 infection?
Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000533.
PubMed

NARASIMMAN M, Hernaez R, Cerda V, Lee M, et al
Hepatocellular carcinoma surveillance may be associated with potential psychological harms of in patients with cirrhosis.
Hepatology. 2023 Jul 4. doi: 10.1097/HEP.0000000000000528.
PubMed Abstract available

IAVARONE M, Nault JC, Cabibbo G, Torres F, et al
Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology.
Hepatology. 2023 Jul 3. doi: 10.1097/HEP.0000000000000527.
PubMed Abstract available

A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.
Hepatology. 2023;78:3-5.
PubMed

CHEEMA MRS
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2023;78:E18.
PubMed

LEE J, Westphal M, Vali Y, Boursier J, et al
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
Hepatology. 2023;78:258-271.
PubMed Abstract available

WEGERMANN K, Diehl AM
Population-based proteomics: Platforms to advance diagnosis and treatment of metabolic liver diseases.
Hepatology. 2023;78:8-9.
PubMed

CHE Y, Chen G, Guo Q, Duan Y, et al
Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.
Hepatology. 2023;78:88-102.
PubMed Abstract available

IRFAN R, Kumar S
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
Hepatology. 2023;78:E8.
PubMed

PENNISI G, Enea M, Falco V, Aithal GP, et al
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Hepatology. 2023;78:195-211.
PubMed Abstract available

DO A, Lim JK
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI.
Hepatology. 2023;78:6-7.
PubMed

NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study).
Hepatology. 2023;78:272-283.
PubMed Abstract available

ABOZAID YJ, Ayada I, van Kleef LA, Vallerga CL, et al
Plasma proteomic signature of fatty liver disease: The Rotterdam Study.
Hepatology. 2023;78:284-294.
PubMed Abstract available

KONG M, Dong W, Kang A, Kuai Y, et al
Regulatory role and translational potential of CCL11 in liver fibrosis.
Hepatology. 2023;78:120-135.
PubMed Abstract available

GUO C, Liu W, Liu Z, Cai J, et al
Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
Hepatology. 2023;78:45-57.
PubMed Abstract available

ZHU H, Yang B
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
Hepatology. 2023;78:E3.
PubMed

VERMA M, Brahmania M, Fortune BE, Asrani SK, et al
Patient-centered care: Key elements applicable to chronic liver disease.
Hepatology. 2023;78:307-318.
PubMed Abstract available

July 2023 Hepatology Highlights.
Hepatology. 2023;78:1-2.
PubMed

June 2023

September Hepatology highlights.
Hepatology. 2023 Jun 13. doi: 10.1097/HEP.0000000000000515.
PubMed

PINTER M, Reig M, Cabibbo G
Analysis of individual patient data in patients with hepatocellular carcinoma treated with immunotherapy: A step forward for clinical trial design.
Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000511.
PubMed

DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making.
Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000513.
PubMed Abstract available

TAPPER EB, Lai JC
Time to embrace PROMIS-29 as the standard health-related quality of life instrument for patients with cirrhosis.
Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000508.
PubMed

SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
PubMed Abstract available

YIM SY, Lee JS
Reply: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000501.
PubMed

HENRY L, Younossi ZM
Reply: NAFLD/MAFLD: One size does not fit all, certainly not for children!
Hepatology. 2023;77:E191.
PubMed

HEGARTY R, Dhawan A
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!
Hepatology. 2023;77:E190.
PubMed

SARKAR M, Flemming JA
Letter to the Editor: Influence of maternal NAFLD on infant weight-the real precursor to NAFLD in offspring?
Hepatology. 2023;77:E180.
PubMed

LEE JM, Joo I
The international quest for the imaging diagnosis of liver cancer.
Hepatology. 2023;77:1839-1842.
PubMed

CANNELLA R, Dioguardi Burgio M, Sartoris R, Gregory J, et al
Adherence to LI-RADS and EASL high-risk population criteria: A systematic review.
Hepatology. 2023;77:1958-1967.
PubMed Abstract available

BOMMENA S, Mahmud N, Boike JR, Thornburg BG, et al
The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study.
Hepatology. 2023;77:2041-2051.
PubMed Abstract available

HSU CL, Lang S, Demir M, Fouts DE, et al
Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.
Hepatology. 2023;77:2073-2083.
PubMed Abstract available

NAGALO BM, Zhou Y, Loeuillard EJ, Dumbauld C, et al
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
Hepatology. 2023;77:1943-1957.
PubMed Abstract available

LIM M, Muquith M, Miramontes B, Lee CJ, et al
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
Hepatology. 2023 Jun 1. doi: 10.1097/HEP.0000000000000494.
PubMed Abstract available

May 2023

AWAN MZUA
Letter to the editor: Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000493.
PubMed

JESUDIAN AB, Fortune BE
The PROs and cons of crystalline lactulose for suspected covert hepatic encephalopathy among patients with cirrhosis and activity impairment: Are we using the right assessments?
Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000497.
PubMed

NEJAK-BOWEN K, Monga SP
Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
PubMed Abstract available

Erratum: Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
Hepatology. 2023 May 26. doi: 10.1097/HEP.0000000000000450.
PubMed

CARR RM, Li Y, Chau L, Friedman ES, et al
An integrated analysis of fecal microbiome and metabolomic features distinguish Non-cirrhotic NASH from healthy control populations.
Hepatology. 2023 May 25. doi: 10.1097/HEP.0000000000000474.
PubMed Abstract available

GILGENKRANTZ H, Paradis V, Lotersztajn S
Cell metabolism-based therapy for liver fibrosis, repair and hepatocellular carcinoma.
Hepatology. 2023 May 23. doi: 10.1097/HEP.0000000000000479.
PubMed Abstract available

LV Y, Han G
Reply: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000475.
PubMed

YIN HJ, Wan YM
Letter to the editor: Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000476.
PubMed

KIM BK, Bergstrom J, Loomba R, Tamaki N, et al
Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study.
Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470.
PubMed Abstract available

August Hepatology Highlights.
Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000468.
PubMed

SINGAL AG, Llovet JM, Yarchoan M, Mehta N, et al
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology. 2023 May 19. doi: 10.1097/HEP.0000000000000466.
PubMed

TONON M, Balcar L, Semmler G, Calvino V, et al
Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
PubMed Abstract available

VITTAL A, Niewisch MR, Bhala S, Kudaravalli P, et al
Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.
Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000461.
PubMed Abstract available

HUANG DQ, Tran A, Yeh ML, Yasuda S, et al
Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.
Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
PubMed Abstract available

MALLET M, Silaghi CA, Sultanik P, Conti F, et al
Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis.
Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000456.
PubMed Abstract available

JI J, Ji F, Bayarsaikhan E
Intratumoral microbiota in hepatocellular carcinoma: A new kid on the block?
Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000454.
PubMed

ANDRISANI O
Two important players in poor prognosis hepatocellular carcinoma (HCC): Extrachromosomal circular DNA (eccDNA) and its passenger, the oncogenic miR-17~92 locus.
Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000453.
PubMed

MEHTA N, Kelley RK, Yao FY
Refining the approach to down-staging for hepatocellular carcinoma prior to liver transplantation: Patient selection, local-regional treatments, and systemic therapies.
Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000452.
PubMed

Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
PubMed

KANZAKI H, Katz C, Hoshida Y
Matrisomic characterization of hepatocellular carcinoma to inform individualized patient management.
Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000443.
PubMed

ANSTEE QM, Lucas KJ, Francque S, Abdelmalek MF, et al
Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study.
Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000439.
PubMed Abstract available

LI G, Chen H, Shen F, Smithson SB, et al
Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis.
Hepatology. 2023 May 3. doi: 10.1097/HEP.0000000000000433.
PubMed Abstract available

SANGHA K, Chang ST, Cheung R, Deshpande VS, et al
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
Hepatology. 2023;77:1702-1711.
PubMed Abstract available

EBRAHIMI F, Ludvigsson JF
Letter to the editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
Hepatology. 2023;77:E107-E108.
PubMed

RINELLA ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology. 2023;77:1797-1835.
PubMed

KNIGHT GM, Thornburg B, Salem R
Reply: Discussing the place of TIPS in non-cirrhotic patients with chronic extra hepatic portal vein occlusion refractory to standard of care therapy.
Hepatology. 2023;77:E93-E94.
PubMed

GU W, Queck A, Trebicka J, Praktiknjo M, et al
Reply: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
Hepatology. 2023;77:E101.
PubMed

ARTRU F, Rautou PE, Denys A
Letter to the editor: discussing the place of TIPS in noncirrhotic patients with chronic extrahepatic portal vein occlusion (EHPVO).
Hepatology. 2023;77:E91-E92.
PubMed

BERARDI G, Ratti F, Sposito C, Nebbia M, et al
Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.
Hepatology. 2023;77:1527-1539.
PubMed Abstract available

CUCCHETTI A, Casadei-Gardini A
Liver resection for HCC in patients with metabolic syndrome: questions answered, questions raised.
Hepatology. 2023;77:1463-1464.
PubMed

WEN Y, Emontzpohl C, Xu L, Atkins CL, et al
Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis.
Hepatology. 2023;77:1580-1592.
PubMed Abstract available

ZHANG S, Wan D, Zhu M, Wang G, et al
CD11b + CD43 hi Ly6C lo splenocyte-derived macrophages exacerbate liver fibrosis via spleen-liver axis.
Hepatology. 2023;77:1612-1629.
PubMed Abstract available

LUO W, Wang Y, Li Y, Zhang T, et al
Letter to the editor: Adipose lipolysis is important for ethanol to induce fatty liver in the NIAAA murine model of chronic and binge ethanol feeding.
Hepatology. 2023;77:E88-E89.
PubMed

ZABRANSKY DJ, Danilova L, Leatherman JM, Lopez-Vidal TY, et al
Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
Hepatology. 2023;77:1566-1579.
PubMed Abstract available

JUAREZ-FERNANDEZ M, Goikoetxea-Usandizaga N, Porras D, Garcia-Mediavilla MV, et al
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
Hepatology. 2023;77:1654-1669.
PubMed Abstract available

MATHUR M, Yeh YT, Arya RK, Jiang L, et al
Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding.
Hepatology. 2023;77:1688-1701.
PubMed Abstract available

LI S, Xia H, Wang Z, Zhang X, et al
Intratumoural microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related hepatocellular carcinoma.
Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000427.
PubMed Abstract available

ZOU S, Chen S, Rao G, Zhang G, et al
Extrachromosomal circular MiR-17-92 amplicon promotes hepatocellular carcinoma.
Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000435.
PubMed Abstract available

AHMED A, Arshad MW, Ibrahim H
Letter to the editor: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000429.
PubMed

CULLARO G
Reply: Variability in serum creatinine is associated with waitlist and post-liver transplant mortality in patients with cirrhosis.
Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000434.
PubMed

May 2023 Hepatology Highlights.
Hepatology. 2023;77:1461-1462.
PubMed

April 2023

KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
PubMed Abstract available

July 2023 Hepatology Highlights.
Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000425.
PubMed

ADAMS LA, Schulte PJ, Allen AM
Use of non-invasive scores to predict hepatic steatosis: Flaws and caveats.
Hepatology. 2023 Apr 27. doi: 10.1097/HEP.0000000000000419.
PubMed

HUNG MH, Chang CW, Wang KC, Chaisaingmongkol J, et al
Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation.
Hepatology. 2023 Apr 26. doi: 10.1097/HEP.0000000000000420.
PubMed Abstract available

UFERE NN
Home is where the liver is?: moving beyond readmissions to time at home as a patient-centered and pragmatic quality measure in cirrhosis care.
Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000415.
PubMed

MALHI H, Shah V, Gores GJ
Thematic reviews: the future of hepatology.
Hepatology. 2023 Apr 19. doi: 10.1097/HEP.0000000000000409.
PubMed

TAPPER EB, Ospina E, Salim N, Chen X, et al
Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient reported outcomes - the Mi-Kristal RCT.
Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000408.
PubMed Abstract available

DANIEL N, Genua F, Jenab M, Mayen AL, et al
The role of the gut microbiome in the development of hepatobiliary cancers.
Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
PubMed Abstract available

MAESO-DIAZ R, Du K, Pan C, Guy CD, et al
Targeting senescent hepatocytes using the THBD-PAR1 inhibitor Vorapaxar ameliorates NAFLD progression.
Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000401.
PubMed Abstract available

JILG N, Baumert TF
Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants.
Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000400.
PubMed

HARTL L, Reiberger T, Trauner M
Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
PubMed

UMAR S, Nadeem A, Nadeem M
Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
PubMed

RAABE J, Kaiser KM, ToVinh M, Finnemann C, et al
Identification and characterisation of a hepatic IL-13 producing ILC3-like population potentially involved in liver fibrosis.
Hepatology. 2023 Apr 10. doi: 10.1097/HEP.0000000000000350.
PubMed Abstract available

HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
PubMed Abstract available

FRIEDMAN SL, Sanyal AJ
The future of hepatology.
Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000389.
PubMed Abstract available

ARUMUGAM S, Li B, Boodapati SLT, Nathanson MH, et al
Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation.
Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000388.
PubMed Abstract available

TANG D, Kroemer G, Kang R
Ferroptosis in hepatocellular carcinoma: from bench to bedside.
Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000390.
PubMed Abstract available

June 2023 Hepatology Highlights.
Hepatology. 2023 Apr 5. doi: 10.1097/HEP.0000000000000391.
PubMed

TIAN Y, Jellinek MJ, Mehta K, Seok SM, et al
Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.
Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000375.
PubMed Abstract available

DESERT R, Chen W, Ge X, Viel R, et al
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome.
Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000362.
PubMed Abstract available

VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Samala N, et al
CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
Hepatology. 2023;77:1241-1252.
PubMed Abstract available

GUERRIERI F, Levrero M
HBV, mitochondrial stress, and liver fibrosis: chicken or the egg.
Hepatology. 2023;77:1088-1089.
PubMed

LIU Z, Tan M, Ding H
Letter to the Editor: Contrast-enhanced CT and liver surface nodularity for the diagnosis of portosinusoidal vascular disorder: a case-control study.
Hepatology. 2023;77:E71.
PubMed

SINGH SP, Mondia N
Letter to the Editor: Much more needed in natural history of Alagille syndrome.
Hepatology. 2023;77:E78.
PubMed

SCHILSKY ML, Roberts EA, Bronstein JM, Dhawan A, et al
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
Hepatology. 2023;77:1428-1455.
PubMed

YIP TC, Vilar-Gomez E, Petta S, Yilmaz Y, et al
Geographical similarity and differences in the burden and genetic predisposition of NAFLD.
Hepatology. 2023;77:1404-1427.
PubMed Abstract available

LI HX, Xie ZQ, Yang ZM, Tang CX, et al
Letter to the Editor: Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
Hepatology. 2023;77:E67-E68.
PubMed

AFONSO MB, Islam T, Magusto J, Amorim R, et al
RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease.
Hepatology. 2023;77:1319-1334.
PubMed Abstract available

TORRES S, Ortiz C, Bachtler N, Gu W, et al
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
Hepatology. 2023;77:1228-1240.
PubMed Abstract available

KARDASHIAN A, Serper M, Terrault N, Nephew LD, et al
Health disparities in chronic liver disease.
Hepatology. 2023;77:1382-1403.
PubMed Abstract available

LOPEZ-VICARIO C, Sebastian D, Casulleras M, Duran-Guell M, et al
Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease.
Hepatology. 2023;77:1303-1318.
PubMed Abstract available

YANG F, Jiang S, Zheng Y
Letter to the Editor: Is eliminating METTL1-mediated accumulation of PMN-MDSCs sufficient to prevent hepatocellular carcinoma recurrence after radiofrequency ablation?
Hepatology. 2023;77:E62-E63.
PubMed

DEPRINCE A, Hennuyer N, Kooijman S, Pronk ACM, et al
Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.
Hepatology. 2023;77:1287-1302.
PubMed Abstract available

JIANG M, Li F, Liu Y, Gu Z, et al
Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.
Hepatology. 2023;77:1164-1180.
PubMed Abstract available

ZENG X, Liao G, Li S, Liu H, et al
Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.
Hepatology. 2023;77:1122-1138.
PubMed Abstract available

ZHOU Y, Jia K, Wang S, Li Z, et al
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7-acetylated and cytoplasm-translocated G protein GalphaS.
Hepatology. 2023;77:1106-1121.
PubMed Abstract available

March 2023

ELHENCE H, Dodge JL, Farias AJ, Lee BP, et al
Quantifying days at home in patients with cirrhosis: a national cohort study.
Hepatology. 2023 Mar 31. doi: 10.1097/HEP.0000000000000370.
PubMed Abstract available

TRIPATHI D, Reiberger T
Letter to the editor: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
Hepatology. 2023 Mar 30. doi: 10.1097/HEP.0000000000000359.
PubMed

KWONG AJ, Zhang KY, Ebel N, Mannalithara A, et al
MELD 3.0 for adolescent liver transplant candidates.
Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000352.
PubMed Abstract available

ELIAS G, Schonfeld M, Saleh S, Parrish M, et al
Sepsis induced endothelial dysfunction drives acute-on-chronic liver failure via Angiopoietin-2-HGF-C/EBPbeta pathway.
Hepatology. 2023 Mar 22. doi: 10.1097/HEP.0000000000000354.
PubMed Abstract available

HONG T, Xiong X, Chen Y, Wang Q, et al
Parathyroid hormone receptor-1 signaling aggravates hepatic fibrosis through upregulating cAMP response element binding protein-like 2.
Hepatology. 2023 Mar 21. doi: 10.1097/HEP.0000000000000333.
PubMed Abstract available

MAK LY, Yuen MF, Seto WK
Reply: hepatic steatosis and glycemic burden in chronic hepatitis b.
Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000374.
PubMed

HUANG SC, Kao JH
Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
PubMed

AHMED HS, Long MT
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000378.
PubMed

LI Z, Zhang L, Li J
Letter to the Editor: the associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality.
Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000377.
PubMed

ZHANG W, Wang MK, Yao D, Zhao HJ, et al
Letter to the editor: hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy.
Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000372.
PubMed

ROWE IA, Villanueva C, Shearer JE, Torres F, et al
Quantifying the benefit of non-selective beta-blockers in the prevention of hepatic decompensation: a Bayesian re-analysis of the PREDESCI trial.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000342.
PubMed Abstract available

ALLAIRE M, Thabut D
Reply: portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000358.
PubMed

May 2023 Hepatology Highlights.
Hepatology. 2023 Mar 8. doi: 10.1097/HEP.0000000000000355.
PubMed

SMITH ML, Wade JB, Wolstenholme J, Bajaj JS, et al
Gut microbiome-brain-cirrhosis axis.
Hepatology. 2023 Mar 6. doi: 10.1097/HEP.0000000000000344.
PubMed Abstract available

GE J, Digitale JC, Pletcher MJ, Lai JC, et al
Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study.
Hepatology. 2023;77:834-850.
PubMed Abstract available

VAN KLEEF LA, de Knegt RJ
Modifiable risk factors for fatty liver disease: Time to act.
Hepatology. 2023;77:712-714.
PubMed

LUO W, Gu Y, Zhang T
Letter to the editor: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage HCC.
Hepatology. 2023;77:E51-E52.
PubMed

SUN Y, Zhang J, Wang H, Wang W, et al
Letter to the editor: Fatty liver and mortality in populations who are elderly.
Hepatology. 2023;77:E47-E48.
PubMed

TARLOW BD, Kim WR, Mannalithara A, Kwo PY, et al
Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
Hepatology. 2023;77:851-861.
PubMed Abstract available

JIANG ST, Xu YY, Lu X
Letter to the editor: Focus on metabolic dysfunction-associated fatty liver disease, even if patients have a history of excessive alcohol consumption.
Hepatology. 2023;77:E43-E44.
PubMed

UDOMPAP P, Therneau TM, Canning RE, Benson JT, et al
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population.
Hepatology. 2023;77:931-941.
PubMed Abstract available

XIE J, Huang H, Liu Z, Li Y, et al
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study.
Hepatology. 2023;77:949-964.
PubMed Abstract available

FONTANA RJ, Liou I, Reuben A, Suzuki A, et al
AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.
Hepatology. 2023;77:1036-1065.
PubMed

NING C, Jiang ST, Sang XT
Letter to the editor: Reflection on the no-association between the presence of fatty liver disease and mortality in the elderly.
Hepatology. 2023;77:E39-E40.
PubMed

CANIVET CM, Costentin C, Irvine KM, Delamarre A, et al
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
Hepatology. 2023;77:920-930.
PubMed Abstract available

VAN KLEEF LA, de Knegt RJ, Brouwer WP
Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
Hepatology. 2023;77:942-948.
PubMed Abstract available

LI S, Zhou B, Xue M, Zhu J, et al
Macrophage-specific FGF12 promotes liver fibrosis progression in mice.
Hepatology. 2023;77:816-833.
PubMed Abstract available

CRESPO M, Nikolic I, Mora A, Rodriguez E, et al
Myeloid p38 activation maintains macrophage-liver crosstalk and BAT thermogenesis through IL-12-FGF21 axis.
Hepatology. 2023;77:874-887.
PubMed Abstract available

CHAN CY, Yuen VW, Chiu DK, Goh CC, et al
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Hepatology. 2023;77:729-744.
PubMed Abstract available

February 2023

ZANETTO A, Campello E, Senzolo M, Simioni P, et al
The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review.
Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000349.
PubMed Abstract available

TAPPER EB, Serper M, Goldberg D
Implementing pragmatic clinical trials in hepatology.
Hepatology. 2023 Feb 27. doi: 10.1097/HEP.0000000000000345.
PubMed Abstract available

DU K, Maeso-Diaz R, Oh SH, Wang E, et al
Targeting YAP-mediated hepatic stellate cell death susceptibility and senescence for treatment of liver fibrosis.
Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000326.
PubMed Abstract available

LI J, Chen J, Lee PMY, Zhang J, et al
Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
PubMed Abstract available

NICOARA-FARCAU O, Lozano JJ, Alonso C, Sidorova J, et al
Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis.
Hepatology. 2023 Feb 23. doi: 10.1097/HEP.0000000000000316.
PubMed Abstract available

GAWRIEH S, Lake JE, Debroy P, Sjoquist JA, et al
Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
Hepatology. 2023 Feb 22. doi: 10.1097/HEP.0000000000000313.
PubMed Abstract available

CHENG L, Deepak RNVK, Wang G, Meng Z, et al
Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKalpha mediating lipid metabolism and tumorigenesis.
Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000314.
PubMed Abstract available

Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
PubMed

ZHANG J, Lyu Z, Li B, You Z, et al
P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
PubMed Abstract available

WU N, Zhou T, Carpino G, Baiocchi L, et al
Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
PubMed Abstract available

KUNDU D, Kennedy L, Zhou T, Ekser B, et al
p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
PubMed Abstract available

AMENT CE, Steinmann S, Evert K, Pes GM, et al
Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
PubMed Abstract available

HU Y, Li Z, Jiang Y, Wang X, et al
Letter to the Editor: More efforts for the meta-analysis of the association between hepatic steatosis and HBV-related HCC.
Hepatology. 2023 Feb 9. doi: 10.1097/HEP.0000000000000332.
PubMed

April 2023 Hepatology Highlights.
Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000325.
PubMed

SCHRADER JA, Burkard TL, Bruggemann Y, Gomer A, et al
Epidermal growth factor receptor modulates hepatitis e virus entry in human hepatocytes -HEP-22-1113.
Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000308.
PubMed Abstract available

ROWE IA, Allen AM
Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
Hepatology. 2023 Feb 6. doi: 10.1097/HEP.0000000000000327.
PubMed

PATOULIAS D
Letter to the Editor: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000311.
PubMed

PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes?
Hepatology. 2023 Feb 3. doi: 10.1097/HEP.0000000000000312.
PubMed

February 2023 Hepatology Highlights.
Hepatology. 2023;77:339-340.
PubMed

WANG M, Sarkar M, Mehta N
Now you see it, now you don't: Estrogen exposure and obesity effects on HCA development and regression.
Hepatology. 2023;77:341-343.
PubMed

LARRUE H, Bureau C
Transjugular intrahepatic portosystemic shunt in portal hypertension: How to go further while staying on track?
Hepatology. 2023;77:344-346.
PubMed

LI J, Nguyen MH
Letter to the editor: Screening for fatty liver disease and fibrosis in the elderly population: A call for action.
Hepatology. 2023;77:E28-E29.
PubMed

VANDRIEL SM, Li LT, She H, Wang JS, et al
Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
Hepatology. 2023;77:512-529.
PubMed Abstract available

HABASH N, Ibrahim SH
The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
Hepatology. 2023;77:347-349.
PubMed

SHAN J, Megarbane A, Chouchane A, Karthik D, et al
Genetic predisposition to porto-sinusoidal vascular disorder: A functional genomic-based, multigenerational family study.
Hepatology. 2023;77:501-511.
PubMed Abstract available

HAGSTROM H, Shang Y
Less is more? Screening for steatosis in older populations.
Hepatology. 2023;77:350-351.
PubMed

LIN H, Yip TC, Zhang X, Li G, et al
Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease.
Hepatology. 2023;77:573-584.
PubMed Abstract available

MONDIA N, Singh SP, Mishra AK
Letter to the editor: Risk factors of NAFLD in preterm and low birthweight. More questions than answers!
Hepatology. 2023;77:E17.
PubMed

VAN KLEEF LA, Sonneveld MJ, Kavousi M, Ikram MA, et al
Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study.
Hepatology. 2023;77:585-593.
PubMed Abstract available

XU L, Yang Y, Jiang J, Wen Y, et al
Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production.
Hepatology. 2023;77:456-465.
PubMed Abstract available

INDIRA CHANDRAN V, Wernberg CW, Lauridsen MM, Skytthe MK, et al
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness.
Hepatology. 2023;77:558-572.
PubMed Abstract available

AJOOLABADY A, Kaplowitz N, Lebeaupin C, Kroemer G, et al
Endoplasmic reticulum stress in liver diseases.
Hepatology. 2023;77:619-639.
PubMed Abstract available

January 2023

ADEJUMO AC, Yakovchenko V, Morgan TR, Spoutz P, et al
The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 veterans.
Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000306.
PubMed Abstract available

LUO J, Gong L, Yang Y, Zhang Y, et al
Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in hepatocellular carcinoma.
Hepatology. 2023 Jan 24. doi: 10.1097/HEP.0000000000000299.
PubMed Abstract available

AHMED HS, Wang N, Carr JJ, Ding J, et al
The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multi-cohort study.
Hepatology. 2023 Jan 19. doi: 10.1097/HEP.0000000000000286.
PubMed Abstract available

HUANG DQ, Tamaki N, Lee HW, Park SY, et al
Outcome of untreated low-level viremia vs. antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000037.
PubMed Abstract available

CUNNINGHAM M, Gupta R, Butler M
Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
PubMed Abstract available

EL HAJRA I, Sanduzzi-Zamparelli M, Sapena V, Munoz-Martinez S, et al
Outcome of patients with hepatocellular carcinoma and liver dysfunction under Immunotherapy: a systematic review and meta-analysis.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000030.
PubMed Abstract available

March 2023 Hepatology Highlights.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000289.
PubMed

ALLAIRE M, Thabut D
Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000291.
PubMed Abstract available

LIU F, Liao Z, Qin L, Zhang Z, et al
Targeting VPS72 inhibits ACTL6A/MYC axis activity in hepatocellular carcinoma progression.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000268.
PubMed Abstract available

CASTERA L, Cusi K
Diabetes and cirrhosis: Current concepts on diagnosis and management.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000263.
PubMed Abstract available

YU H, Zhou L, Loong JH, Lam KH, et al
SERPINA12 promotes the tumorigenic capacity of hepatocellular carcinoma stem cells through hyperactivation of AKT/ beta-catenin signaling.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000269.
PubMed Abstract available

GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
PubMed Abstract available

GONG L, Wei F, Gonzalez FJ, Li G, et al
Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000182.
PubMed Abstract available

BEHRENDT P, Gouttenoire J
Editorial in Hepatology Urine: A place where HEV cannot hide!
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000017.
PubMed

HAO L, Zhong W, Woo J, Wei X, et al
Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining A. muciniphila in alcoholic steatohepatitis.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000019.
PubMed Abstract available

YOUNOSSI Z, Golabi P, Paik J, Henry A, et al
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000004.
PubMed Abstract available

LV Y, Han G
Reply to HEP-22-1980 Embolization of large spontaneous shunt for the prevention of hepatic encephalopathy after TIPS: more questions than answers.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000010.
PubMed

SHORT C, Zhong A, Xu J, Mahdi E, et al
TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
PubMed Abstract available

LO GH
Is embolization of large spontaneous shunt effective in the prevention of hepatic encephalopathy after TIPS?
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000007.
PubMed

LEE SH, So J, Shin D
Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
PubMed Abstract available

FU S, Liu M, Zhu C, Zhang H, et al
Regulatory MAIT cells controlled by beta1 adrenergic receptor signaling contribute to hepatocellular carcinoma progression.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000014.
PubMed Abstract available

WANG S, Wang R, Xu N, Wei X, et al
SULT2B1-CS-DOCK2 axis regulates effector T cell exhaustion in hepatocellular carcinoma microenvironment.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000025.
PubMed Abstract available

KODAMA T, Takehara T
Is it a prime time for germline genetic testing for hepatocellular carcinoma?
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000033.
PubMed

BHALA N, Ferguson JW, Rajoriya N, Newsome PN, et al
Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000011.
PubMed

WANG CC, Kao JH
Letter to the Editor Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000009.
PubMed

CABIBBO G, Celsa C, Alimenti E, Iavarone M, et al
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced hepatocellular carcinoma: the dark side of the moon.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000205.
PubMed

ZHANG L, Pan Q, Zhang L, Xia H, et al
Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
PubMed Abstract available

FENG Y, Peng B, Li Y, Sun L, et al
Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000209.
PubMed

KHORASANI S, Boike J, Duarte-Rojo A
Will noninvasive screening for fibrosis/steatosis open Pandora's box? Sharing the healthcare burden of state-of-the-art hepatology practice.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000235.
PubMed

MA F, Liu Y, Hu Z, Xue Y, et al
Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000042.
PubMed Abstract available

CHUNG HH
Letter to the Editor: The pathological impact of PAR2 on hepatic insulin resistance.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000284.
PubMed

CHANG D, Truong E, Noureddin M
Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: Accuracy and routine variables are the success keys.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000211.
PubMed

TANTAI X, Wang J, Dai S
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000271.
PubMed

DUAN S, Qin N, Pi J, Sun P, et al
Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000185.
PubMed Abstract available

SHARPTON SR, Loomba R
Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000278.
PubMed Abstract available

KARDASHIAN A, Kushner T, Au JS, Flemming JA, et al
The key role of hepatology providers in optimizing reproductive care in patients with liver disease: a call to action.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000275.
PubMed

CAO J, Bai DS
Letter to the editor: Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
Hepatology. 2023;77:E11.
PubMed

SEMMLER G, Thorhauge KH, Reiberger T, Thiele M, et al
Letter to the editor: Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
Hepatology. 2023;77:E1-E2.
PubMed

WADHWANI SI, Lai JC
The digital determinants of liver disease.
Hepatology. 2023;77:13-14.
PubMed

LINDBLAD KE, Lujambio A
Imaging for better responses to immunotherapy in hepatocellular carcinoma.
Hepatology. 2023;77:6-9.
PubMed

HENSON JB, Wegermann K, Patel YA, Wilder JM, et al
Access to technology to support telehealth in areas without specialty care for liver disease.
Hepatology. 2023;77:176-185.
PubMed Abstract available

GIDENER T, Dierkhising RA, Mara KC, Therneau TM, et al
Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD.
Hepatology. 2023;77:268-274.
PubMed Abstract available

ZHANG L, Guo GL
Gut-specific inhibition of PPARalpha as a novel approach of NAFLD treatment.
Hepatology. 2023;77:15-17.
PubMed

GOYAL NP, Rosenthal SB, Nasamran C, Behling CA, et al
Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children.
Hepatology. 2023;77:197-212.
PubMed Abstract available

HAGSTROM H
A new model for estimation of significant fibrosis in primary care. SAFE to use?
Hepatology. 2023;77:18-19.
PubMed

SRIPONGPUN P, Kim WR, Mannalithara A, Charu V, et al
The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care.
Hepatology. 2023;77:256-267.
PubMed Abstract available

REN Z, Simons PIHG, Wesselius A, Stehouwer CDA, et al
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study.
Hepatology. 2023;77:230-238.
PubMed Abstract available

KOMUTA M, Ueno A, Sakamoto M
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer.
Hepatology. 2023;77:10-12.
PubMed

January 2023 Hepatology Highlights.
Hepatology. 2023;77:1-2.
PubMed

January 2023 Hepatology Highlights.
Hepatology. 2023;77:1-2.
PubMed

December 2022

ZHANG J, Xu Y, Lu X, Zhao H, et al
Letter to the editor: NAFLD and sarcopenia: Association or causation?
Hepatology. 2022;76:E119-E120.
PubMed

JIANG ST, Zhang L, Xu YY, Lu X, et al
Letter to the editor: Complications following SARS-CoV-2 infection in patients with chronic liver disease.
Hepatology. 2022;76:E116.
PubMed

XUN Z, Zhao H
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?
Hepatology. 2022;76:E127-E128.
PubMed

SHEARER AM, Wang Y, Fletcher EK, Rana R, et al
PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference.
Hepatology. 2022;76:1778-1793.
PubMed Abstract available

SINN DH, Kang D, Kang M, Guallar E, et al
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study.
Hepatology. 2022;76:1746-1754.
PubMed Abstract available

KIM Y, Chang Y, Ryu S, Wild SH, et al
NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status.
Hepatology. 2022;76:1755-1765.
PubMed Abstract available

SHARMA D, Ben Yakov G, Kapuria D, Viana Rodriguez G, et al
Tip of the iceberg: A comprehensive review of liver disease in Inborn errors of immunity.
Hepatology. 2022;76:1845-1861.
PubMed Abstract available

RATZIU V, Anstee QM, Wong VW, Schattenberg JM, et al
An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project.
Hepatology. 2022;76:1766-1777.
PubMed Abstract available

HUANG M, Jiao J, Cai H, Zhang Y, et al
C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner.
Hepatology. 2022;76:1706-1722.
PubMed Abstract available

FENG R, Kan K, Sticht C, Li Y, et al
A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions.
Hepatology. 2022;76:1673-1689.
PubMed Abstract available

HONG F, Lin CY, Yan J, Dong Y, et al
Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response-dependent destabilization of tumor protein P53.
Hepatology. 2022;76:1587-1601.
PubMed Abstract available

ASIF B, Ortiz V, Conboy CB, Diaz LA, et al
Hepatology Highlights.
Hepatology. 2022;76:1555-1556.
PubMed

November 2022

CHUNG HH
Letter to the editor: The perspective of GLP-1/GLP-2 receptors against NASH via diverse regulation.
Hepatology. 2022;76:E106-E107.
PubMed

ATTIA D, Gomaa A, Abdel Alem S
Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD.
Hepatology. 2022;76:E100.
PubMed

VAN KLEEF LA, de Knegt RJ
The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach?
Hepatology. 2022;76:1243-1245.
PubMed

AMADOU C, Nabi O, Serfaty L, Lacombe K, et al
Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
Hepatology. 2022;76:1438-1451.
PubMed Abstract available

SHANG Y, Nasr P, Widman L, Hagstrom H, et al
Risk of cardiovascular disease and loss in life expectancy in NAFLD.
Hepatology. 2022;76:1495-1505.
PubMed Abstract available

OLIVEIRA CP
Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?
Hepatology. 2022;76:1246-1247.
PubMed

YOUNOSSI ZM, Paik JM, Al Shabeeb R, Golabi P, et al
Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
Hepatology. 2022;76:1423-1437.
PubMed Abstract available

RIMOLA J, Sapena V, Brancatelli G, Darnell A, et al
Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria.
Hepatology. 2022;76:1318-1328.
PubMed Abstract available

VILAR-GOMEZ E, Pirola CJ, Sookoian S, Wilson LA, et al
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.
Hepatology. 2022;76:1482-1494.
PubMed Abstract available

ZHANG X, Wong GL, Yip TC, Cheung JTK, et al
Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
Hepatology. 2022;76:1409-1422.
PubMed Abstract available

LEI L, Bruneau A, El Mourabit H, Guegan J, et al
Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis.
Hepatology. 2022;76:1360-1375.
PubMed Abstract available

TOMLINSON JL, Penrice DD, Ramkissoon R, Udompap P, et al
Hepatology highlights.
Hepatology. 2022;76:1231-1232.
PubMed

FOUAD Y, Abdel Dayem WA, Mehrez M
Letter to the editor: Apples should be compared with apples.
Hepatology. 2022;76:E101.
PubMed

October 2022

Erratum for Jiang L, et al. calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway.
Hepatology. 2022 Oct 26. doi: 10.1002/hep.32796.
PubMed

LAM YK, Yu J, Huang H, Ding X, et al
TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
Hepatology. 2022 Oct 11. doi: 10.1002/hep.32802.
PubMed Abstract available

RAHAL HK, Tabibian JH, Issaka RB, Quezada S, et al
Diversity, equity, and inclusion in gastroenterology and hepatology: A survey of where we stand.
Hepatology. 2022 Oct 11. doi: 10.1002/hep.32757.
PubMed Abstract available

WU T, Povero D, Parthasarathy G, Idalsoaga F, et al
Hepatology highlights.
Hepatology. 2022;76:901-902.
PubMed

SUCHMAN K, Da BL
Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC.
Hepatology. 2022;76:E78-E79.
PubMed

DEVARBHAVI H, Kurien SS
Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury.
Hepatology. 2022;76:E71-E72.
PubMed

BARROW F, Revelo XS
The B side of B cells in NAFLD.
Hepatology. 2022;76:914-916.
PubMed

PAI RK, Jairath V, Hogan M, Zou G, et al
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
Hepatology. 2022;76:1150-1163.
PubMed Abstract available

LASCHTOWITZ A, Tacke F
Many roads lead to Rome: The FGF4-AMP-activated protein kinase-Caspase 6 signal axis in NAFLD and NASH.
Hepatology. 2022;76:911-913.
PubMed

MARTINEZ-ARRANZ I, Bruzzone C, Noureddin M, Gil-Redondo R, et al
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
Hepatology. 2022;76:1121-1134.
PubMed Abstract available

KARL M, Hasselwander S, Zhou Y, Reifenberg G, et al
Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.
Hepatology. 2022;76:1135-1149.
PubMed Abstract available

SONG L, Wang L, Hou Y, Zhou J, et al
FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis.
Hepatology. 2022;76:1105-1120.
PubMed Abstract available

WANG H, Zhang B, Li R, Chen J, et al
KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration.
Hepatology. 2022;76:967-981.
PubMed Abstract available

BAPTISSART M, Bradish CM, Jones BS, Walsh E, et al
Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome.
Hepatology. 2022;76:1090-1104.
PubMed Abstract available

WANG H, Zhou Y, Xu H, Wang X, et al
Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Hepatology. 2022;76:951-966.
PubMed Abstract available

BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
PubMed Abstract available

September 2022

VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
Reply to the Letter to the Editor: "Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?"
Hepatology. 2022 Sep 30. doi: 10.1002/hep.32813.
PubMed

VAZ K, Little R, Majeed A, Roberts S, et al
Letter to the Editor: Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?
Hepatology. 2022 Sep 28. doi: 10.1002/hep.32811.
PubMed

ALLEGRETTI AS
NGAL in AKI and cirrhosis - ready for prime time?
Hepatology. 2022 Sep 28. doi: 10.1002/hep.32807.
PubMed

YIP TC, Wong VW, Wong GL
Does hepatic steatosis impact chronic hepatitis B?
Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.
PubMed

MAK LY, Hui RW, Lee CH, Mao X, et al
Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
PubMed Abstract available

GAMBINO C, Piano S, Stenico M, Tonon M, et al
Diagnostic and prognostic performance of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and AKI.
Hepatology. 2022 Sep 20. doi: 10.1002/hep.32799.
PubMed Abstract available

MANNA D, Reghupaty SC, Camarena MDC, Mendoza RG, et al
Melanoma Differentiation Associated Gene-9/Syndecan Binding Protein (MDA-9/SDCBP) Promotes Hepatocellular Carcinoma (HCC).
Hepatology. 2022 Sep 19. doi: 10.1002/hep.32797.
PubMed Abstract available

JACHS M, Tillmann HL
Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
PubMed

MAO X, Cheung KS, Peng C, Mak LY, et al
Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
PubMed Abstract available

CHEN YT, Su YC, Or YE, Cheng CF, et al
CD8(+) T cell memory is sustained in mice by hepatic stellate cells.
Hepatology. 2022 Sep 15. doi: 10.1002/hep.32788.
PubMed Abstract available

BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
PubMed Abstract available

LIU Y, Zhang J, Xu Y, Lu X, et al
Letter to the editor: Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients.
Hepatology. 2022 Sep 14. doi: 10.1002/hep.32785.
PubMed

VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
Reply to the Letter to the Editor: "Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients".
Hepatology. 2022 Sep 13. doi: 10.1002/hep.32784.
PubMed

LESLIE J, Hunter JE, Collins A, Rushton A, et al
c-Rel dependant Chk2 signalling regulates the DNA damage response limiting hepatocarcinogenesis.
Hepatology. 2022 Sep 11. doi: 10.1002/hep.32781.
PubMed Abstract available

LEE YT, Fujiwara N, Yang JD, Hoshida Y, et al
Risk stratification and early detection biomarkers for precision hepatocellular carcinoma screening.
Hepatology. 2022 Sep 9. doi: 10.1002/hep.32779.
PubMed Abstract available

DELLINGER RW, Holmes HE, Hu-Seliger T, Butt RW, et al
NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial.
Hepatology. 2022 Sep 9. doi: 10.1002/hep.32778.
PubMed Abstract available

Retracted: Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
Hepatology. 2022 Sep 8. doi: 10.1002/hep.32736.
PubMed

LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
PubMed Abstract available

DUAN Z
Postvaccination COVID-19 related mortality in patients with cirrhosis:who is the culprit?
Hepatology. 2022 Sep 5. doi: 10.1002/hep.32750.
PubMed

HUANG H, Wu L, Lu L, Zhang Z, et al
Single-cell Transcriptomics Uncovers Cellular Architecture and Developmental Trajectories in Hepatoblastoma.
Hepatology. 2022 Sep 4. doi: 10.1002/hep.32775.
PubMed Abstract available

KNORR J, Kaufmann B, Inzaugarat ME, Holtmann TM, et al
Interleukin-18 signaling promotes activation of hepatic stellate cells in murine liver fibrosis.
Hepatology. 2022 Sep 4. doi: 10.1002/hep.32776.
PubMed Abstract available

VAN ZWOL W, Rimbert A, Wolters JC, Smit M, et al
Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion.
Hepatology. 2022 Sep 2. doi: 10.1002/hep.32709.
PubMed Abstract available

JENSEN DM, Rzepczynski A, Jensen EE, Reau N, et al
The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.
Hepatology. 2022;76:854-859.
PubMed

CULLARO G, Verna EC, McCulloch CE, Lai JC, et al
Improving the Model for End-Stage Liver Disease with sodium by incorporating kidney dysfunction types.
Hepatology. 2022;76:689-699.
PubMed Abstract available

ZABALETA N, Torella L, Weber ND, Gonzalez-Aseguinolaza G, et al
mRNA and gene editing: Late breaking therapies in liver diseases.
Hepatology. 2022;76:869-887.
PubMed Abstract available

HARRIS EN
Will inhibition of cellular crosstalk resolve liver fibrosis?
Hepatology. 2022;76:558-560.
PubMed

ZHENG M, Allington G, Vilarinho S
Genomic medicine for liver disease.
Hepatology. 2022;76:860-868.
PubMed

CALCAGNO DM, Chu A, Gaul S, Taghdiri N, et al
NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH.
Hepatology. 2022;76:727-741.
PubMed Abstract available

LIN Y, Dong MQ, Liu ZM, Xu M, et al
A strategy of vascular-targeted therapy for liver fibrosis.
Hepatology. 2022;76:660-675.
PubMed Abstract available

ALVA-RUIZ R, Ahn JC, Udompap P, Diaz LA, et al
Hepatology highlights.
Hepatology. 2022;76:539-540.
PubMed

August 2022

QUECK A, Praktiknjo M, Jansen C, Trebicka J, et al
Response to the letter to the editor: "Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS".
Hepatology. 2022 Aug 25. doi: 10.1002/hep.32754.
PubMed

LUO W, Wang Y, Li Y, Zhang T, et al
Letter to the editor: Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
Hepatology. 2022 Aug 25. doi: 10.1002/hep.32755.
PubMed

HU S, Monga SP
Response to the "Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin".
Hepatology. 2022 Aug 24. doi: 10.1002/hep.32694.
PubMed

JOHN BV, Dahman B
COVID-19 related mortality in Cirrhosis is not associated with Proton Pump Inhibitor Exposure.
Hepatology. 2022 Aug 24. doi: 10.1002/hep.32748.
PubMed

LO GH
Could COVID-19 vaccination reduce post-infection mortality in most cirrhotic patients ?
Hepatology. 2022 Aug 24. doi: 10.1002/hep.32751.
PubMed

JOHN BV, Dahman B
COVID-19 Vaccination and mortality in Decompensated Cirrhosis.
Hepatology. 2022 Aug 24. doi: 10.1002/hep.32749.
PubMed

LEE HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ, et al
Attacking the Public Health Crisis of Hepatocellular Carcinoma at its Roots.
Hepatology. 2022 Aug 21. doi: 10.1002/hep.32741.
PubMed

DONNE R, Lujambio A
The Liver Cancer Immune Microenvironment: Therapeutic Implications for Hepatocellular Carcinoma.
Hepatology. 2022 Aug 21. doi: 10.1002/hep.32740.
PubMed Abstract available

ZONG C, Meng Y, Ye F, Yang X, et al
AIF1(+) CSF1R(+) MSCs, induced by TNF-alpha, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis.
Hepatology. 2022 Aug 21. doi: 10.1002/hep.32738.
PubMed Abstract available

SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
PubMed Abstract available

DEMORY A, Peron JM, Calderaro J, Selves J, et al
Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
Hepatology. 2022 Aug 18. doi: 10.1002/hep.32734.
PubMed Abstract available

LOUREIRO D, Tout I, Narguet S, Bed CM, et al
Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
PubMed Abstract available

GOUON-EVANS V, Fiorotto R
Fibroblasts to hepatocytes: a non-stop flight into cell therapy for liver diseases?
Hepatology. 2022 Aug 11. doi: 10.1002/hep.32725.
PubMed

LIU T, Wang Q, Zhou L, Zhang P, et al
Intrahepatic paracrine signaling by CLCF1 ameliorates diet-induced NASH in mice.
Hepatology. 2022 Aug 11. doi: 10.1002/hep.32719.
PubMed Abstract available

WU Y, Hao X, Wei H, Sun R, et al
TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
PubMed Abstract available

RODRIGUEZ TC, Kwan S, Smith JL, Dadafarin S, et al
Multi-omics characterization of mouse hepatoblastoma identifies novel YAP1 target genes.
Hepatology. 2022 Aug 6. doi: 10.1002/hep.32713.
PubMed Abstract available

LIU X, Wang K, Wang L, Kong L, et al
Hepatocyte Ltb4r1 promotes NAFLD development in obesity.
Hepatology. 2022 Aug 5. doi: 10.1002/hep.32708.
PubMed Abstract available

LIANG B, Wang H, Qiao Y, Wang X, et al
Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation driven hepatocarcinogenesis.
Hepatology. 2022 Aug 3. doi: 10.1002/hep.32693.
PubMed Abstract available

VIZZUTTI F, Celsa C, Calvaruso V, Enea M, et al
Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model.
Hepatology. 2022 Aug 3. doi: 10.1002/hep.32704.
PubMed Abstract available

PENUELAS-HARO I, Espinosa-Sotelo R, Crosas-Molist E, Herranz-Iturbide M, et al
The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing hepatocellular carcinoma progression.
Hepatology. 2022 Aug 3. doi: 10.1002/hep.32702.
PubMed Abstract available

NING C, Zhang XM, Sang XT, Zhao HT, et al
Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte beta-catenin.
Hepatology. 2022 Aug 2. doi: 10.1002/hep.32695.
PubMed

PATTOU F, Lasailly G, Raverdy V, Caiazzo R, et al
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty.
Hepatology. 2022;76:E51-E52.
PubMed

JIANG ST, Zhang JW, Lu X, Xu YY, et al
Letter to the editor: Discussion on application scenario of cell-free DNA fragmentomics in primary liver cancer.
Hepatology. 2022;76:E44.
PubMed

JINDAL A
Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
Hepatology. 2022;76:E42.
PubMed

GUIDOTTI LG, La Vecchia C, Colombo M
Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
Hepatology. 2022;76:300-302.
PubMed

PANIGRAHI MK, Anirvan P
Letter to the editor: Using angiotensin-converting enzyme inhibitors to prevent liver-related events in NAFLD-Revisiting the renin-angiotensin-aldosterone system pathways.
Hepatology. 2022;76:E32-E33.
PubMed

MAYO MJ
Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
Hepatology. 2022;76:518-531.
PubMed Abstract available

VOS MB, Van Natta ML, Blondet NM, Dasarathy S, et al
Randomized placebo-controlled trial of losartan for pediatric NAFLD.
Hepatology. 2022;76:429-444.
PubMed Abstract available

AGOPIAN VG, Yang JD, Zhu Y, You S, et al
Early detection of primary liver cancer using plasma cell-free DNA fragmentomics: Do all the pieces come together?
Hepatology. 2022;76:289-291.
PubMed

MAO Y, Han CY, Hao L, Lee Y, et al
p21-activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation.
Hepatology. 2022;76:345-356.
PubMed Abstract available

VALAINATHAN SR, Sartoris R, Elkrief L, Magaz M, et al
Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.
Hepatology. 2022;76:418-428.
PubMed Abstract available

PAIS R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, et al
Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
Hepatology. 2022;76:456-468.
PubMed Abstract available

GUNEWARDENA S, Huck I, Walesky C, Robarts D, et al
Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans.
Hepatology. 2022;76:372-386.
PubMed Abstract available

SOFTIC S, Kohli R
Pediatric NASH therapies: A speedbump on the road to success.
Hepatology. 2022;76:292-294.
PubMed

ZHANG X, Wang Z, Tang W, Wang X, et al
Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
Hepatology. 2022;76:317-329.
PubMed Abstract available

ZHANG X, Wong GL, Yip TC, Tse YK, et al
Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
Hepatology. 2022;76:469-482.
PubMed Abstract available

HAN B, Francipane MG, Cheikhi A, Johnson J, et al
Fat-associated lymphoid clusters as expandable niches for ectopic liver development.
Hepatology. 2022;76:357-371.
PubMed Abstract available

XIONG H, Zhang C, Han L, Xu T, et al
Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity.
Hepatology. 2022;76:387-403.
PubMed Abstract available

July 2022

SUN N, Zhang C, Lee YT, Tran BV, et al
HCC EV ECG Score: An Extracellular Vesicle-based Protein Assay for Detection of Early-Stage Hepatocellular Carcinoma.
Hepatology. 2022 Jul 31. doi: 10.1002/hep.32692.
PubMed Abstract available

BAI Y, Yang Z, Xu X, Ding W, et al
Direct chemical induction of hepatocyte-like cells with capacity for liver repopulation.
Hepatology. 2022 Jul 26. doi: 10.1002/hep.32686.
PubMed Abstract available

QUECK A, Schwierz L, Gu W, Ferstl PG, et al
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
Hepatology. 2022 Jul 23. doi: 10.1002/hep.32676.
PubMed Abstract available

HU S, Cao C, Poddar M, Delgado E, et al
Hepatocyte beta-Catenin Loss is Compensated by Insulin-mTORC1 Activation to Promote Liver Regeneration.
Hepatology. 2022 Jul 21. doi: 10.1002/hep.32680.
PubMed Abstract available

PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
PubMed

LIU X, Tan S, Liu H, Jiang J, et al
Hepatocyte-derived MASP1-enriched small extracellular vesicles activate hepatic stellate cells to promote liver fibrosis.
Hepatology. 2022 Jul 18. doi: 10.1002/hep.32662.
PubMed Abstract available

LAI SW
Aspirin use and the risk of hepatocellular carcinoma.
Hepatology. 2022 Jul 17. doi: 10.1002/hep.32674.
PubMed

ZHONG D, Cai J, Hu C, Chen J, et al
Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
Hepatology. 2022 Jul 15. doi: 10.1002/hep.32671.
PubMed Abstract available

JIN ZC, Chen JJ, Luo B, Zhang WH, et al
Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
PubMed

POZO-MORALES M, Garteizgogeascoa I, Perazzolo C, So J, et al
In vivo imaging of calcium dynamics in zebrafish hepatocytes.
Hepatology. 2022 Jul 13. doi: 10.1002/hep.32663.
PubMed Abstract available

YANG F, Jiang ST, Lu X, Xu Y, et al
Letter to the editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
Hepatology. 2022 Jul 11. doi: 10.1002/hep.32659.
PubMed

BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
PubMed Abstract available

CHANG D, Truong E, Mena EA, Pacheco F, et al
Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis.
Hepatology. 2022 Jul 9. doi: 10.1002/hep.32655.
PubMed Abstract available

ZHANG Y, Ye S, Lu W, Zhong J, et al
RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
Hepatology. 2022 Jul 7. doi: 10.1002/hep.32651.
PubMed Abstract available

KOVALIC AJ, Lee TP, Da BL
Letter to the editor: L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Hepatology. 2022 Jul 5. doi: 10.1002/hep.32643.
PubMed

RYDELL GE, Ringlander J, Larsson SB, Hellstrand K, et al
Letter to the editor: Alu-PCR design may have compromised detection of integrated core HBV DNA.
Hepatology. 2022;76:E23.
PubMed

DANAN G, Teschke R
Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation.
Hepatology. 2022;76:E27.
PubMed

RASCHI E, Caraceni P
Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?
Hepatology. 2022;76:E25-E26.
PubMed

KIVLIGHN S, Schuur E, Gish RG, Cryer D, et al
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention.
Hepatology. 2022;76:E7-E8.
PubMed

TAO X, Zhao Y, Chen L, Zeng M, et al
Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
Hepatology. 2022;76:E13-E14.
PubMed

KAPPUS MR, Patel YA, Duarte-Rojo A
Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
Hepatology. 2022;76:12-14.
PubMed

PISCAGLIA F
Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm.
Hepatology. 2022;76:6-8.
PubMed

HAYASHI PH, Lucena MI, Fontana RJ, Bjornsson ES, et al
A revised electronic version of RUCAM for the diagnosis of DILI.
Hepatology. 2022;76:18-31.
PubMed Abstract available

SERPER M, Parikh ND, Thiele G, Ovchinsky N, et al
Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
Hepatology. 2022;76:251-274.
PubMed Abstract available

LEWIS JH
Digitizing DILI: Who can? RUCAM? RECAM?
Hepatology. 2022;76:3-5.
PubMed

KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
Hepatology. 2022;76:186-195.
PubMed Abstract available

STINE JG, Schreibman IR, Faust AJ, Dahmus J, et al
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
Hepatology. 2022;76:172-185.
PubMed Abstract available

DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
Hepatology. 2022;76:275-285.
PubMed

POVERO D, Ahn JC, Arnold J, Udompap P, et al
Hepatology Highlights.
Hepatology. 2022;76:1-2.
PubMed

FAN Y, Jiang ST, Yong-Chang Z
Letter to the Editor: Some reflection on the research related to METTL1 promoting radiotherapy resistance in hepatocellular carcinoma.
Hepatology. 2022 Jul 1. doi: 10.1002/hep.32644.
PubMed

SCHMID CD, Olsavszky V, Reinhart M, Weyer V, et al
ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver.
Hepatology. 2022 Jul 1. doi: 10.1002/hep.32641.
PubMed Abstract available

June 2022

TRAN NH, Munoz S, Thompson S, Hallemeier CL, et al
Hepatocellular Carcinoma Down-Staging for Liver Transplantation in the Era of Systemic Combined Therapy with Anti-VEGF/TKI and Immunotherapy.
Hepatology. 2022 Jun 28. doi: 10.1002/hep.32613.
PubMed Abstract available

MALHI H, Gores GJ
What is Hepatology looking for Version 2.0?
Hepatology. 2022 Jun 26. doi: 10.1002/hep.32637.
PubMed

JIANG ST, Xu YY, Lu X
Letter to the Editor: Using intratumoral steatosis to predict the efficacy of combination therapy in nonviral hepatocellular carcinoma.
Hepatology. 2022 Jun 25. doi: 10.1002/hep.32628.
PubMed

ZHAO K, Guo F, Wang J, Zhong Y, et al
Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
PubMed Abstract available

YUAN T, Zhou T, Qian M, Du J, et al
SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
Hepatology. 2022 Jun 17. doi: 10.1002/hep.32621.
PubMed Abstract available

JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
PubMed Abstract available

LI B, Yu D
Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?
Hepatology. 2022 Jun 15. doi: 10.1002/hep.32616.
PubMed

XU C, Fan J, Liu D, Tuerdi A, et al
Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
PubMed Abstract available

LIAO J, Yi Y, Yue X, Wu X, et al
METTL1 is required for non-homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy.
Hepatology. 2022 Jun 14. doi: 10.1002/hep.32615.
PubMed Abstract available

MA X, Chen A, Melo L, Clemente-Sanchez A, et al
Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
PubMed Abstract available

AHMAD A
Letter to the Editor: The Precise Relationship Between MELD and Survival Without a Liver Transplant.
Hepatology. 2022 Jun 11. doi: 10.1002/hep.32602.
PubMed Abstract available

XU J, Wang Y, Khoshdeli M, Peach M, et al
IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
PubMed Abstract available

HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
PubMed Abstract available

DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
PubMed Abstract available

TESTINO G
Letter to the editor: Chronic liver disease among adolescents and young adults: Alcohol use disorder identification.
Hepatology. 2022;75:1662-1663.
PubMed

JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
Hepatology. 2022;75:1480-1490.
PubMed Abstract available

SANDAHL TD, Gormsen LC, Kjaergaard K, Vendelbo MH, et al
The pathophysiology of Wilson's disease visualized: A human (64) Cu PET study.
Hepatology. 2022;75:1461-1470.
PubMed Abstract available

QIAN Q, Li Y, Fu J, Leng D, et al
Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
Hepatology. 2022;75:1507-1522.
PubMed Abstract available

VILAR-GOMEZ E, Nephew LD, Vuppalanchi R, Gawrieh S, et al
High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population.
Hepatology. 2022;75:1491-1506.
PubMed Abstract available

PSARAKI A, Ntari L, Karakostas C, Korrou-Karava D, et al
Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases.
Hepatology. 2022;75:1590-1603.
PubMed Abstract available

ALVA-RUIZ R, Wu T, Idalsoaga F, Ramkissoon R, et al
Hepatology highlights.
Hepatology. 2022;75:1363-1364.
PubMed

May 2022

ZHANG JW, Fang J, Xun Z, Xu Y, et al
Letter to the Editor: Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in the Real World.
Hepatology. 2022 May 23. doi: 10.1002/hep.32588.
PubMed

KIMURA Y, Koyama Y, Taura K, Kudoh A, et al
Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice.
Hepatology. 2022 May 23. doi: 10.1002/hep.32586.
PubMed Abstract available

JALAN-SAKRIKAR N, Brevini T, Huebert RC, Sampaziotis F, et al
Organoids and Regenerative Hepatology.
Hepatology. 2022 May 21. doi: 10.1002/hep.32583.
PubMed Abstract available

LI L, Zhang Y, Zhou Y, Hu H, et al
Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma.
Hepatology. 2022 May 21. doi: 10.1002/hep.32584.
PubMed Abstract available

HARTL L, Haslinger K, Angerer M, Semmler G, et al
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
PubMed Abstract available

XU W, Cui C, Cui C, Chen Z, et al
Hepatocellular Cystathionine gamma lyase/Hydrogen sulfide Attenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.
Hepatology. 2022 May 19. doi: 10.1002/hep.32577.
PubMed Abstract available

PILLING LC, Atkins JL, Melzer D
Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort.
Hepatology. 2022 May 14. doi: 10.1002/hep.32575.
PubMed Abstract available

MURAI H, Kodama T, Maesaka K, Tange S, et al
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
Hepatology. 2022 May 14. doi: 10.1002/hep.32573.
PubMed Abstract available

BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
PubMed Abstract available

KIM KE, Lee J, Shin HJ, Jeong EA, et al
Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice.
Hepatology. 2022 May 13. doi: 10.1002/hep.32569.
PubMed Abstract available

SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
PubMed Abstract available

MEHTA S, Asrani SK
The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
Hepatology. 2022 May 5. doi: 10.1002/hep.32559.
PubMed

ANDERSEN JB
Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
PubMed

GULATI P, Taneja S, Duseja A, Singh V, et al
Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
PubMed

LIU JJ, Xin B, Du L, Chen L, et al
Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
Hepatology. 2022 May 3. doi: 10.1002/hep.32555.
PubMed Abstract available

HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
Fontan-associated liver disease.
Hepatology. 2022;75:1300-1321.
PubMed

LEE CH, Lui DTW, Lam KSL
Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
Hepatology. 2022;75:1340.
PubMed

CHUNG HH
Letter to the editor: The multiple mechanisms of fructose disrupt gut-liver axis and metabolic regulation.
Hepatology. 2022;75:1338-1339.
PubMed

ASRANI SK, Ghabril MS, Kuo A, Merriman RB, et al
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
Hepatology. 2022;75:1289-1299.
PubMed Abstract available

PAIK JM, Kabbara K, Eberly KE, Younossi Y, et al
Global burden of NAFLD and chronic liver disease among adolescents and young adults.
Hepatology. 2022;75:1204-1217.
PubMed Abstract available

KUREBAYASHI Y, Matsuda K, Ueno A, Tsujikawa H, et al
Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments.
Hepatology. 2022;75:1139-1153.
PubMed Abstract available

ZHANG JL, Du BB, Zhang DH, Li H, et al
OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
Hepatology. 2022;75:1218-1234.
PubMed Abstract available

SONG J, Song H, Wei H, Sun R, et al
Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
Hepatology. 2022;75:1181-1193.
PubMed Abstract available

REN QN, Zhang H, Sun CY, Zhou YF, et al
Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.
Hepatology. 2022;75:1123-1138.
PubMed Abstract available

CONBOY CB, Penrice DD, Watkins R, Diaz LA, et al
Hepatology highlights.
Hepatology. 2022;75:1071-1072.
PubMed

QIN Y, Li A, Liu B, Gao M, et al
Comment on "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD".
Hepatology. 2022 May 1. doi: 10.1002/hep.32551.
PubMed

SANGRO B, Argemi J
Immunotherapy in hepatocellular carcinoma - No rush despite the hype.
Hepatology. 2022 May 1. doi: 10.1002/hep.32550.
PubMed

April 2022

SHAH PA, Patil R, Harrison SA
NAFLD-related hepatocellular carcinoma: The growing challenge.
Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
PubMed Abstract available

KUMAR A, Rajani D, Kumar S
Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
PubMed

YAN T, Luo Y, Yan N, Hamada K, et al
Intestinal Peroxisome Proliferator-Activated Receptor alpha-Fatty Acid Binding Protein 1 Axis Modulates Nonalcoholic Steatohepatitis.
Hepatology. 2022 Apr 23. doi: 10.1002/hep.32538.
PubMed Abstract available

CHEN L, Dong J, Meng Q, Song Z, et al
Reply to the comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
Hepatology. 2022 Apr 19. doi: 10.1002/hep.32530.
PubMed

IVANICS T, Claasen MP, Patel MS, Hansen BE, et al
Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
Hepatology. 2022 Apr 18. doi: 10.1002/hep.32532.
PubMed

JIANG ST, Zhang JW, Lu X, Xu YY, et al
Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
Hepatology. 2022 Apr 17. doi: 10.1002/hep.32533.
PubMed

RAO Z, Li F, Guan Z, Zhou H, et al
Comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
Hepatology. 2022 Apr 16. doi: 10.1002/hep.32529.
PubMed

XU MX, Tan J, Ge CX, Dong W, et al
TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7.
Hepatology. 2022 Apr 16. doi: 10.1002/hep.32526.
PubMed Abstract available

AHN JC, Lauzon M, Luu M, Noureddin M, et al
Racial and ethnic disparities in early treatment with immunotherapy for advanced hepatocellular carcinoma in the United States.
Hepatology. 2022 Apr 16. doi: 10.1002/hep.32527.
PubMed Abstract available

TRIPATHI D, Bureau C
Prophylactic embolization of large spontaneous portosystemic shunts with TIPS: A panacea for post TIPS hepatic encephalopathy?
Hepatology. 2022 Apr 16. doi: 10.1002/hep.32525.
PubMed

ZHU Y, Gu L, Lin X, Zhou X, et al
P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis.
Hepatology. 2022 Apr 10. doi: 10.1002/hep.32518.
PubMed Abstract available

DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
PubMed Abstract available

KHADERI S, Kanwal F
Changing Epidemiology of Hepatocellular Cancer in the United States: winning the battle but it is not over yet.
Hepatology. 2022 Apr 7. doi: 10.1002/hep.32512.
PubMed

TCHORZ JS
Re-tuning hepatocytes improves their functional engraftment.
Hepatology. 2022 Apr 7. doi: 10.1002/hep.32513.
PubMed

GOEPPERT B, Roessler S
New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation.
Hepatology. 2022 Apr 6. doi: 10.1002/hep.32509.
PubMed

MANDATO C, Vajro P
Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
PubMed

KRAMER JR, Natarajan Y, Dai J, Yu X, et al
Response to letter to the editor from Zhou et al (Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease).
Hepatology. 2022 Apr 2. doi: 10.1002/hep.32503.
PubMed

ZHOU Y, Chu W, Wu X, Zhou H, et al
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.
PubMed

TOMLINSON JL, Ahn JC, Povero D, Ramkissoon R, et al
Hepatology Highlights.
Hepatology. 2022;75:775-776.
PubMed

AHUJA P, Bi X, Ng CF, Tse MCL, et al
Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77- fibroblast growth factor 21 pathway.
Hepatology. 2022 Apr 1. doi: 10.1002/hep.32501.
PubMed Abstract available

SINGAL AK, Kwo P, Kwong A, Liangpunsakul S, et al
Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
Hepatology. 2022;75:1026-1037.
PubMed Abstract available

SINGH SA, Madan K, Gupta S, Indrayan A, et al
Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
Hepatology. 2022;75:1067-1068.
PubMed

WANG S, Whitlock R, Lai JC, Taneja S, et al
Reply.
Hepatology. 2022;75:1068-1069.
PubMed

JAIN A, Sharma BC
Reply.
Hepatology. 2022;75:1066-1067.
PubMed

COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
Hepatology. 2022;75:1056-1057.
PubMed

PAILHORIES H, Boursier J, Diehl AM
Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle.
Hepatology. 2022;75:782-784.
PubMed

NEIL DAH, Minervini M, Smith ML, Hubscher SG, et al
Banff consensus recommendations for steatosis assessment in donor livers.
Hepatology. 2022;75:1014-1025.
PubMed Abstract available

KWAN SY, Jiao J, Joon A, Wei P, et al
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
Hepatology. 2022;75:955-967.
PubMed Abstract available

ZHOU HZ, Li F, Cheng ST, Xu Y, et al
DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
Hepatology. 2022;75:847-865.
PubMed Abstract available

SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
Hepatology. 2022;75:881-897.
PubMed Abstract available

March 2022

CULLARO G, Hsu CY, Lai JC
Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
PubMed Abstract available

LEE SH, Yim SY, Jeong YS, Li QX, et al
Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
Hepatology. 2022 Mar 29. doi: 10.1002/hep.32490.
PubMed Abstract available

JAVITT NB
Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
PubMed

DENG R, Liu S, Shen S, Guo H, et al
Circulating hepatitis B virus RNA: From biology to clinical applications.
Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
PubMed Abstract available

CAI HX, Xin C, Wang XP
ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a murine model of Wilson's disease.
Hepatology. 2022 Mar 27. doi: 10.1002/hep.32484.
PubMed Abstract available

WANG T, Xu C, Zhang Z, Wu H, et al
Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
PubMed Abstract available

D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
PubMed Abstract available

CHEN L, Dong J, Liao S, Wang S, et al
Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury.
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32471.
PubMed Abstract available

FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
PubMed Abstract available

CREEDEN JF, Kipp ZA, Xu M, Flight RM, et al
Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents.
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32467.
PubMed Abstract available

HOU J
Drinking vinegar, a potential adjuvant for immunotherapy of hepatocellular carcinoma?
Hepatology. 2022 Mar 18. doi: 10.1002/hep.32463.
PubMed

GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
PubMed Abstract available

LV Y, Chen H, Luo B, Bai W, et al
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
PubMed Abstract available

BASS LM, Ye W, Hawthorne K, Leung DH, et al
The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
PubMed Abstract available

HU C, Xu B, Wang X, Wan WH, et al
Gut microbiota-derived short-chain fatty acids regulates group 3 innate lymphoid cells in hepatocellular carcinoma.
Hepatology. 2022 Mar 9. doi: 10.1002/hep.32449.
PubMed Abstract available

FOERSTER F, Gairing SJ, Ilyas SI, Galle PR, et al
Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.
Hepatology. 2022 Mar 7. doi: 10.1002/hep.32447.
PubMed Abstract available

BARNAULT R, Verzeroli C, Fournier C, Michelet M, et al
Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation.
Hepatology. 2022 Mar 7. doi: 10.1002/hep.32446.
PubMed Abstract available

HE Y, Luo J, Zhang G, Jin Y, et al
Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.
Hepatology. 2022 Mar 4. doi: 10.1002/hep.32444.
PubMed Abstract available

NIE YZ, Zheng YW, Taniguchi H
Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity.
Hepatology. 2022 Mar 4. doi: 10.1002/hep.32443.
PubMed Abstract available

LU Z, Liu R, Wang Y, Jiao M, et al
TET2 Inactivation Restrains IL-10-producing Regulatory B cells to Enable Anti-tumor Immunity in Hepatocellular Carcinoma.
Hepatology. 2022 Mar 4. doi: 10.1002/hep.32442.
PubMed Abstract available

PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
Diabetes Medications and Risk of Hepatocellular Carcinoma.
Hepatology. 2022 Mar 3. doi: 10.1002/hep.32439.
PubMed Abstract available

Hepato Liver Cancer logy highlights.
Hepatology. 2022;75:503-504.
PubMed

HILSCHER MB, Shah VH
A NET gain in our understanding of acute liver failure.
Hepatology. 2022;75:511-513.
PubMed

LUO MS, Huang GJ
Letter to the editor: The addition of C-reactive protein and von Willebrand factor to Model for End-Stage Liver Disease-Sodium.
Hepatology. 2022;75:763-764.
PubMed

WU JW, Tseng TC, Kao JH
Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.
Hepatology. 2022;75:760-761.
PubMed

BEKKI Y, Fenig Y
Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
Hepatology. 2022;75:754.
PubMed

Seeking Editor for Clinical Liver Disease.
Hepatology. 2022;75:i.
PubMed

VON MEIJENFELDT FA, Stravitz RT, Zhang J, Adelmeijer J, et al
Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.
Hepatology. 2022;75:623-633.
PubMed Abstract available

GOIKOETXEA-USANDIZAGA N, Serrano-Macia M, Delgado TC, Simon J, et al
Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
Hepatology. 2022;75:550-566.
PubMed Abstract available

REN R, He Y, Ding D, Cui A, et al
Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPalpha-miRNA-223 axis.
Hepatology. 2022;75:646-660.
PubMed Abstract available

TAMAKI N, Imajo K, Sharpton S, Jung J, et al
Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Hepatology. 2022;75:661-672.
PubMed Abstract available

WANG C, Zhang L, Sun Z, Yuan X, et al
Dedifferentiation-associated inflammatory factors of long-term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment.
Hepatology. 2022 Mar 1. doi: 10.1002/hep.32436.
PubMed Abstract available

KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
PubMed Abstract available

IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
PubMed Abstract available

February 2022

ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
PubMed Abstract available

SUTHEN SD, Lim CJ, Nguyen PHD, Dutertre CA, et al
Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma.
Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419.
PubMed Abstract available

FAN L, Pan Q, Yang W, Koo SC, et al
A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis.
Hepatology. 2022 Feb 18. doi: 10.1002/hep.32412.
PubMed Abstract available

IVANICS T, Murillo Perez CF, Claasen MP, Patel MS, et al
Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection.
Hepatology. 2022 Feb 18. doi: 10.1002/hep.32411.
PubMed Abstract available

EFE C, Harputluoglu M, Karadag Soylu N, Yilmaz S, et al
Liver transplantation following SARS-CoV-2 vaccination-induced liver failure.
Hepatology. 2022 Feb 17. doi: 10.1002/hep.32409.
PubMed

WANG Z, Yu J, Liang P
Reply to "Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!"
Hepatology. 2022 Feb 9. doi: 10.1002/hep.32402.
PubMed

JINDAL A, Mukund A
Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!
Hepatology. 2022 Feb 9. doi: 10.1002/hep.32401.
PubMed

NOUREDDIN M, Abdelmalek MF
ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.
PubMed

YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
PubMed Abstract available

ALVAREZ CS, Petrick JL, Parisi D, McMahon BJ, et al
Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.
Hepatology. 2022 Feb 5. doi: 10.1002/hep.32394.
PubMed Abstract available

JEON Y, Kwon SM, Rhee H, Yoo JE, et al
Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
PubMed Abstract available

ZANETTO A, Campello E, Spiezia L, Burra P, et al
Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.
PubMed

LEMOINE CP, Superina R
Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.
PubMed

LUO C, Xin H, Zhou Z, Hu Z, et al
Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
PubMed Abstract available

LEE V, Wong TC
Reply to "prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant".
Hepatology. 2022 Feb 2. doi: 10.1002/hep.32379.
PubMed

WATKINS R, Ilyas SI, Penrice DD, Conboy CB, et al
Hepatology Highlights.
Hepatology. 2022;75:241-242.
PubMed

ROGAL S, Hansen L, Patel A, Ufere NN, et al
AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.
PubMed

KARATAYLI E, Lammert F
Vulnerability to alcohol-associated liver disease: A tale of two systems.
Hepatology. 2022;75:246-247.
PubMed

HEY P, Gow P
Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion.
Hepatology. 2022;75:495-496.
PubMed

GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
Hepatology. 2022;75:379-390.
PubMed Abstract available

VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
Hepatology. 2022;75:419-429.
PubMed Abstract available

RAMANI K, Robinson AE, Berlind J, Fan W, et al
S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.
Hepatology. 2022;75:280-296.
PubMed Abstract available

LIN T, Wang S, Munker S, Jung K, et al
Follistatin-controlled activin-HNF4alpha-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
Hepatology. 2022;75:322-337.
PubMed Abstract available

KIM KY, Kim JO, Kim YS, Choi JE, et al
Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study.
Hepatology. 2022;75:391-402.
PubMed Abstract available

January 2022

JIANG SY, Yang X, Yang Z, Li JW, et al
Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis.
Hepatology. 2022 Jan 31. doi: 10.1002/hep.32381.
PubMed Abstract available

DE A, Keisham A, Duseja A
Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.
PubMed

JANG H, Lee YB, Moon H, Chung JW, et al
Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
PubMed Abstract available

KUMAR A, Sharma P, Arora A
Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.
PubMed

LIU F, Zhang W, Liu H
Letter to the Editor: Hepatocyte Proliferation Peak and beta-Oxidation in Liver Regeneration after Partial Hepatectomy.
Hepatology. 2022 Jan 26. doi: 10.1002/hep.32357.
PubMed

PAIK JM, Henry L, Younossi ZM
Response to: Chronic Liver Disease Among Adolescent and Young Adult: Alcohol Use Disorder Identification- Letter to the Editor. Hepatology 2022.
Hepatology. 2022 Jan 25. doi: 10.1002/hep.32362.
PubMed

SAHAI P, Jindal A, Mukund A
Letter to the Editor: Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
Hepatology. 2022 Jan 25. doi: 10.1002/hep.32354.
PubMed

LI YT, Liu CJ, Kao JH, Lin LF, et al
Metastatic Tumor Antigen 1 Contributes to Hepatocarcinogenesis Posttranscriptionally Through Novel RNA Binding Function.
Hepatology. 2022 Jan 24. doi: 10.1002/hep.32356.
PubMed Abstract available

HAN J, Wang B, Liu W, Wang S, et al
Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: A population-based analysis.
Hepatology. 2022 Jan 24. doi: 10.1002/hep.32355.
PubMed Abstract available

FANG Y, Liu W, Tang Z, Ji X, et al
MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack.
Hepatology. 2022 Jan 19. doi: 10.1002/hep.32348.
PubMed Abstract available

KHATIB SA, Ma L, Dang H, Forgues M, et al
Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in hepatocellular carcinoma.
Hepatology. 2022 Jan 16. doi: 10.1002/hep.32345.
PubMed Abstract available

LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
PubMed Abstract available

WU T, Simonetto DA, Halamka JD, Shah VH, et al
The Digital Transformation of Hepatology: The Patient is Logged In.
Hepatology. 2022 Jan 13. doi: 10.1002/hep.32329.
PubMed Abstract available

JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
PubMed Abstract available

RAMADORI P, Kam S, Heikenwalder M
T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis.
Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336.
PubMed Abstract available

SANDMANN L, Cornberg M
Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
PubMed

WANG Z, Liu M, Zhang DZ, Wu SS, et al
Microwave Ablation versus Laparoscopic Resection as First-line Therapy for Solitary 3-5 cm Hepatocellular Carcinoma.
Hepatology. 2022 Jan 10. doi: 10.1002/hep.32323.
PubMed Abstract available

FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
PubMed Abstract available

MA H, Kang Z, Foo TK, Shen Z, et al
Disrupted BRCA1-PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in Hepatocellular Carcinoma Through cGAS-STING Pathway.
Hepatology. 2022 Jan 10. doi: 10.1002/hep.32335.
PubMed Abstract available

ANDERSSON ER
Outside influence: the extrahepatic duct as a source for bile duct regeneration.
Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
PubMed

MOORE MP, Cunningham RP, Meers GM, Johnson SA, et al
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324.
PubMed Abstract available

TRANAH TH, Shawcross DL
The rise and fall and rise again of ammonia as a therapeutic target in hepatic encephalopathy.
Hepatology. 2022 Jan 7. doi: 10.1002/hep.32319.
PubMed

SHIODE Y, Kodama T, Shigeno S, Murai K, et al
Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
PubMed Abstract available

NG CH, Xiao J, Lim WH, Chin YH, et al
Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
PubMed Abstract available

WU H, Li Y, Shi G, Du S, et al
Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy.
Hepatology. 2022 Jan 6. doi: 10.1002/hep.32316.
PubMed Abstract available

Hepatology Highlights.
Hepatology. 2022;75:1-2.
PubMed

PHAM L, Kennedy L, Baiocchi L, Meadows V, et al
Mast cells in liver disease progression: An update on current studies and implications.
Hepatology. 2022;75:213-218.
PubMed

December 2021

LABENZ C, Labenz J, Galle PR
Letter to the Editor: Evidence on the use of L-ornithine L-aspartate in overt hepatic encephalopathy - but does it really improve prognosis?
Hepatology. 2021 Dec 27. doi: 10.1002/hep.32309.
PubMed

RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.
PubMed

MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
PubMed Abstract available

LAEMMLE A, Haberle J, Willenbring H
Reply to "The Role of Aquaporin 9 in Modeling of Ornithine Transcarbamylase Deficiency".
Hepatology. 2021 Dec 21. doi: 10.1002/hep.32290.
PubMed

KODAMA T, Takehara T
Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.
PubMed

REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
PubMed Abstract available

RICH NE, Singal AG
Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
Hepatology. 2021 Dec 19. doi: 10.1002/hep.32284.
PubMed Abstract available

FRIEDMAN SL, Pinzani M
Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
PubMed Abstract available

CARABALLO GALVA LD, Jiang X, Hussein MS, Zhang H, et al
Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma.
Hepatology. 2021 Dec 12. doi: 10.1002/hep.32279.
PubMed Abstract available

LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
PubMed

LAI JC, Shui AM, Duarte-Rojo A, Ganger DR, et al
Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.
Hepatology. 2021 Dec 4. doi: 10.1002/hep.32268.
PubMed Abstract available

XIN B, Yang M, Wu P, Du L, et al
Enhancing the Therapeutic Efficacy of PD-L1 Antibody for Metastasized Liver Cancer by Overcoming Hepatic Immunotolerance.
Hepatology. 2021 Dec 3. doi: 10.1002/hep.32266.
PubMed Abstract available

SAPISOCHIN G, Ivanics T, Heimbach J
Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
PubMed Abstract available

KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
PubMed Abstract available

2021 Hepatology Referees (Volumes 73 and 74).
Hepatology. 2021;74:3565-3569.
PubMed

CODISPODO G, Brown RS Jr, Hans A, Roccaro G, et al
Hepatology Highlights.
Hepatology. 2021;74:2931-2934.
PubMed

KUMAR K, Kulkarni A, Jagdish RK
Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
Hepatology. 2021;74:3559-3560.
PubMed

AGARWAL A, Sharma S, Saraya A
Letter to the Editor: Defining the Futility for Rescue Transjugular Intrahepatic Portosystemic Shunt Using the Model for End-Stage Liver Disease Score and Lactate in Variceal Bleed.
Hepatology. 2021;74:3556-3557.
PubMed

JINDAL A, Sarin SK, Mukund A
Letter to the Editor: Salvage TIPS for Refractory Variceal Bleed-More Questions Than Answers!
Hepatology. 2021;74:3557-3558.
PubMed

VALENTI LVC, Cherubini A
To Be or Not to Be: The Quest for Patatin-Like Phospholipase Domain Containing 3 p.I148M Function.
Hepatology. 2021;74:2942-2944.
PubMed

GOH GB, Chan WK, Wong VW
Breastfeeding to Prevent NAFLD.
Hepatology. 2021;74:2939-2941.
PubMed

SONG J, Liu Y, Wan J, Zhao GN, et al
SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.
Hepatology. 2021;74:3091-3109.
PubMed Abstract available

WAN J, Zhang Y, Yang D, Liang Y, et al
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
Hepatology. 2021;74:3074-3090.
PubMed Abstract available

TILSON SG, Morell CM, Lenaerts AS, Park SB, et al
Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
Hepatology. 2021;74:2998-3017.
PubMed Abstract available

SHAH NL, Miller JB, Kalman RS, Kumar S, et al
AASLD Educating and Engaging in the Digital Age: Editorial from Communications and Technology Committee.
Hepatology. 2021;74:2935-2938.
PubMed

PARK Y, Sinn DH, Oh JH, Goh MJ, et al
The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.
Hepatology. 2021;74:2988-2997.
PubMed Abstract available

WU T, Luo G, Lian Q, Sui C, et al
Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
Hepatology. 2021;74:3249-3268.
PubMed Abstract available

KUMAR S, Wong R, Newberry C, Yeung M, et al
Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD.
Hepatology. 2021;74:3472-3478.
PubMed

OTT P, Ala A, Askari FK, Czlonkowska A, et al
Designing Clinical Trials in Wilson's Disease.
Hepatology. 2021;74:3460-3471.
PubMed Abstract available

GARCIA-MACIA M, Santos-Ledo A, Leslie J, Paish HL, et al
A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.
Hepatology. 2021;74:3441-3459.
PubMed Abstract available

LANGE AP, Usmani AA, Wald C, Gordon FD, et al
Sinusoidal Obstruction Syndrome in a Young Woman With Antiphospholipid Syndrome on Oral Contraceptives.
Hepatology. 2021;74:3539-3541.
PubMed

HAKIM A, Moll M, Brancale J, Liu J, et al
Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.
Hepatology. 2021;74:3394-3408.
PubMed Abstract available

BAI W, Al-Karaghouli M, Stach J, Sung S, et al
Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
Hepatology. 2021;74:3301-3315.
PubMed Abstract available

RUSYN I, Arzuaga X, Cattley RC, Corton JC, et al
Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.
Hepatology. 2021;74:3486-3496.
PubMed Abstract available

November 2021

JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
"L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
PubMed Abstract available

GHANY MG, King WC, Lisker-Melman M, Sf Lok A, et al
Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk.
Hepatology. 2021 Nov 20. doi: 10.1002/hep.32251.
PubMed Abstract available

LAEMMLE A, Poms M, Hsu B, Borsuk M, et al
Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.
Hepatology. 2021 Nov 16. doi: 10.1002/hep.32247.
PubMed Abstract available

KRAMER JR, Natarajan Y, Dai J, Yu X, et al
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244.
PubMed Abstract available

KIM ER, Park JS, Kim JH, Oh JY, et al
A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
PubMed Abstract available

TIAN L, Zhao L, Sze KM, Kam CS, et al
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
Hepatology. 2021 Nov 12. doi: 10.1002/hep.32236.
PubMed Abstract available

YANG J, Ye J, Ma T, Tang F, et al
TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.
Hepatology. 2021 Nov 12. doi: 10.1002/hep.32234.
PubMed Abstract available

LI H, Lan T, Liu H, Liu C, et al
IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
PubMed Abstract available

WU N, Carpino G, Ceci L, Baiocchi L, et al
MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
PubMed Abstract available

DING MJ, Fang HR, Zhang JK, Shi JH, et al
E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
PubMed Abstract available

KAPLAN A, Brown RS Jr, Buckholz A, Hang TP, et al
Hepatology Highlights.
Hepatology. 2021;74:2329-2332.
PubMed

BERNUAU J, Cazals-Hatem D, Vigrain V, Durand F, et al
Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone.
Hepatology. 2021;74:2922.
PubMed

JINDAL A
Letter to the Editor: Infections in Severe Forms of Alcohol-Associated Liver Disease: Need a Closer Look!
Hepatology. 2021;74:2926-2927.
PubMed

BAZARBASHI AN, Li M, Ryou M
Letter to the Editor: Endoscopic Ultrasound-Guided Coil Therapy for Secondary Prevention After Gastric Variceal Bleeding: A Promising Alternative.
Hepatology. 2021;74:2914.
PubMed

LOU L, Li X
Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto-sinusoidal Vascular Liver Disease.
Hepatology. 2021;74:2910-2911.
PubMed

CHINNADURAI KK, De A, Duseja A, Singh V, et al
Letter to the Editor: Is Balloon-Occluded Retrograde Transvenous Obliteration Superior to Endoscopic Cyanoacrylate in Gastric Varices?
Hepatology. 2021;74:2907-2908.
PubMed

VOJJALA N, Mehtani R, Singh V
Letter to the Editor: Acute Liver Injury Due to Therapeutic Doses of Acetaminophen-Confounders Must Be Ruled Out!
Hepatology. 2021;74:2904.
PubMed

ZHOU J, Bai L, Zhang XJ, Li H, et al
Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications.
Hepatology. 2021;74:2839-2847.
PubMed

INARRAIRAEGUI M, Sangro B
Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?
Hepatology. 2021;74:2333-2335.
PubMed

HU Y, He W, Huang Y, Xiang H, et al
Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
Hepatology. 2021;74:2508-2525.
PubMed Abstract available

DIAZ LA, Idalsoaga F, Fuentes-Lopez E, Marquez-Lomas A, et al
Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study.
Hepatology. 2021;74:2478-2490.
PubMed Abstract available

PAISANT A, Bellal S, Lebigot J, Canivet CM, et al
Imaging Features of Hepatic Small Vessel Neoplasm: Case Series.
Hepatology. 2021;74:2894-2896.
PubMed

VAN DALEM J, Driessen JHM, Burden AM, Stehouwer CDA, et al
Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
Hepatology. 2021;74:2467-2477.
PubMed Abstract available

SUN H, Meng Q, Shi C, Yang H, et al
Hypoxia-Inducible Exosomes Facilitate Liver-Tropic Premetastatic Niche in Colorectal Cancer.
Hepatology. 2021;74:2633-2651.
PubMed Abstract available

BURYSKA S, Ahn JC, Allen AM, Simha V, et al
Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH.
Hepatology. 2021;74:2897-2898.
PubMed

BARCENA-VARELA M, Lujambio A
Dissecting Early Relapse in Liver Cancer, One Cell at a Time.
Hepatology. 2021;74:2891-2893.
PubMed

DRISCOLL J, Wehrkamp C, Ota Y, Thomas JN, et al
Biological Nanotherapeutics for Liver Disease.
Hepatology. 2021;74:2863-2875.
PubMed Abstract available

SIMON TG, Roelstraete B, Sharma R, Khalili H, et al
Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Hepatology. 2021;74:2410-2423.
PubMed Abstract available

JAGDISH RK, Maras JS, Sarin SK
Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
Hepatology. 2021;74:2848-2862.
PubMed Abstract available

October 2021

LAN T, Jiang S, Zhang J, Weng Q, et al
Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
PubMed Abstract available

KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
PubMed Abstract available

MANCUSO A
Portal vein thrombosis in cirrhosis: the issue of treatment.
Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
PubMed Abstract available

LI M, Wong D, Vogel AS, Sack JS, et al
Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
PubMed Abstract available

LUCE E, Steichen C, Allouche M, Messina A, et al
In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
Hepatology. 2021 Oct 23. doi: 10.1002/hep.32211.
PubMed Abstract available

SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
PubMed Abstract available

ZHOU J, Guo L, Ma T, Qiu T, et al
N-Acetylgalactosaminyltransferase-4 protects against hepatic ischaemia/reperfusion injury via blocking ASK1 N-terminal dimerization.
Hepatology. 2021 Oct 18. doi: 10.1002/hep.32202.
PubMed Abstract available

Correction of HEPATOLOGY 2020;71:259-274.
Hepatology. 2021 Oct 12. doi: 10.1002/hep.32036.
PubMed

GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
PubMed Abstract available

SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
PubMed Abstract available

LIU N, Steer CJ, Song G
MicroRNA-206 Enhances Antitumor Immunity by Disrupting the Communication between Malignant Hepatocytes and Tregs in c-Myc Mice.
Hepatology. 2021 Oct 4. doi: 10.1002/hep.32182.
PubMed Abstract available

LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
PubMed Abstract available

ALLAMNENI C, Vora RS, Bamidele AO, Schwartz RE, et al
Hepatology Highlights.
Hepatology. 2021;74:1727-1729.
PubMed

MCCARRON S, Bathon B, Conlon DM, Abbey D, et al
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.
Hepatology. 2021;74:1825-1844.
PubMed Abstract available

EDELSON JC, Rockey DC
Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.
Hepatology. 2021;74:2313-2314.
PubMed

LLEO A, Hirschfield GM
Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
Hepatology. 2021;74:2307.
PubMed

VILARINHO S, Ajmera V, Zheng M, Loomba R, et al
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.
Hepatology. 2021;74:2241-2250.
PubMed

FRANCQUE S
Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!
Hepatology. 2021;74:1730-1733.
PubMed

ZHOU J, Hu M, He M, Wang X, et al
TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.
Hepatology. 2021;74:2133-2153.
PubMed Abstract available

MALESPIN M, May EJ, Nephew LD, Paul S, et al
AASLD Deepens Commitment to Diversity, Equity, and Inclusion.
Hepatology. 2021;74:2216-2225.
PubMed

WALTER A, Rudler M, Olivas P, Moga L, et al
Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
Hepatology. 2021;74:2085-2101.
PubMed Abstract available

GEURTSEN ML, Wahab RJ, Felix JF, Gaillard R, et al
Maternal Early-Pregnancy Glucose Concentrations and Liver Fat Among School-Age Children.
Hepatology. 2021;74:1902-1913.
PubMed Abstract available

NI M, Zhang J, Sosa R, Zhang H, et al
T-Cell Immunoglobulin and Mucin Domain-Containing Protein-4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury.
Hepatology. 2021;74:2118-2132.
PubMed Abstract available

COLUCCI S, Altamura S, Marques O, Dropmann A, et al
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFbeta Pathway Activation.
Hepatology. 2021;74:2186-2200.
PubMed Abstract available

IM YR, Hunter H, de Gracia Hahn D, Duret A, et al
A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD.
Hepatology. 2021;74:1884-1901.
PubMed Abstract available

BARROW F, Khan S, Wang H, Revelo XS, et al
The Emerging Role of B Cells in the Pathogenesis of NAFLD.
Hepatology. 2021;74:2277-2286.
PubMed Abstract available

CHOI WM, Ryu T, Lee JH, Shim YR, et al
Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.
Hepatology. 2021;74:2170-2185.
PubMed Abstract available

CHEN L, Wu N, Kennedy L, Francis H, et al
Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
Hepatology. 2021;74:1845-1863.
PubMed Abstract available

DINANI AM, Kowdley KV, Noureddin M
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
Hepatology. 2021;74:2233-2240.
PubMed Abstract available

YU H, He J, Liu W, Feng S, et al
The Transcriptional Coactivator, ALL1-Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer.
Hepatology. 2021;74:1952-1970.
PubMed Abstract available

GAWRIEH S, Noureddin M, Loo N, Mohseni R, et al
Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Hepatology. 2021;74:1809-1824.
PubMed Abstract available

LUO X, Xiang T, Wu J, Wang X, et al
Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.
Hepatology. 2021;74:2074-2084.
PubMed Abstract available

September 2021

FANG Y, Zhan Y, Xie Y, Du S, et al
Integration of Glucose and Cardiolipin Anabolism Confers Radiation Resistance of Hepatocellular Carcinoma.
Hepatology. 2021 Sep 28. doi: 10.1002/hep.32177.
PubMed Abstract available

LI H, Liu G, Wan X, Zhou L, et al
ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes.
Hepatology. 2021 Sep 28. doi: 10.1002/hep.32176.
PubMed Abstract available

GARCIA-TSAO G
Can we rely on changes in HVPG in patients with cirrhosis?
Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
PubMed Abstract available

ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
PubMed Abstract available

DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
PubMed Abstract available

ZHAO Y, Gao L, Jiang C, Chen J, et al
The Transcription Factor ZHX2 Alleviates Nonalcoholic Steatohepatitis by Transcriptional Activation of PTEN.
Hepatology. 2021 Sep 21. doi: 10.1002/hep.32165.
PubMed Abstract available

ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
PubMed Abstract available

ZHAI LL, Zhen SH, Tang ZG
Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.
Hepatology. 2021 Sep 18. doi: 10.1002/hep.32158.
PubMed Abstract available

FANG AP, Zhang YJ, Chen MS, Zhu HL, et al
Response to "Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival".
Hepatology. 2021 Sep 18. doi: 10.1002/hep.32160.
PubMed Abstract available

WANG S, Whitlock R, Xu C, Taneja S, et al
Frailty is associated with increased risk of cirrhosis disease progression and death.
Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
PubMed Abstract available

HUANG R, Liu J, Wang J, Li J, et al
Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
PubMed Abstract available

DUAN J, Wang Z, Duan R, Yang C, et al
Therapeutic Targeting of Hepatic ACSL4 Ameliorates Non-alcoholic Steatohepatitis in Mice.
Hepatology. 2021 Sep 12. doi: 10.1002/hep.32148.
PubMed Abstract available

CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
PubMed Abstract available

BLOOM PP, Fontana RJ
With Alcohol as the fuel, COVID is the match: Liver Transplantation for Alcoholic liver disease is increasing in the United States.
Hepatology. 2021 Sep 8. doi: 10.1002/hep.32141.
PubMed Abstract available

SHAH BJ, Onken JE, Edgar L, Jou JH, et al
Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows.
Hepatology. 2021 Sep 7. doi: 10.1002/hep.32097.
PubMed

COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
PubMed Abstract available

ZHANG X, Yang H, Zeng S, Tian S, et al
Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
PubMed Abstract available

AN J, Kim D, Oh B, Oh YJ, et al
Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
PubMed Abstract available

GORES GJ, Malhi H
Presenting the New Incoming Editorial Team for HEPATOLOGY: Team Members and Perspectives.
Hepatology. 2021 Sep 2. doi: 10.1002/hep.32137.
PubMed Abstract available

KHAN IW, Ali MA, Lau DTY, Hang TP, et al
Hepatology Highlights.
Hepatology. 2021;74:1137-1140.
PubMed

RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
Hepatology. 2021;74:1674-1686.
PubMed Abstract available

SHARMA S, Gunjan D, Saraya A
Letter to the Editor: Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Rebleeding: A Paradigm Shift?
Hepatology. 2021;74:1721-1722.
PubMed

ZHANG XP, Zhao GD, Liu Q, Liu R, et al
Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion.
Hepatology. 2021;74:1719.
PubMed

SEKAR D, K AP
Letter to the Editor: H19 Promotes HCC Bone Metastasis by Reducing Osteoprotegerin Expression in a PPP1CA/p38MAPK-Dependent Manner and Sponging miR-200b-3p.
Hepatology. 2021;74:1713.
PubMed

CRAXI L
Letter to the Editor: Comment on "The Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases".
Hepatology. 2021;74:1710.
PubMed

ALLEN AM, Neuschwander-Tetri BA
The Importance of Glycemic Equipoise in NASH.
Hepatology. 2021;74:1145-1147.
PubMed

JIANG X, Qian H, Ding WX
New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer.
Hepatology. 2021;74:1141-1144.
PubMed

WANG SS, Tang XT, Lin M, Yuan J, et al
Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
Hepatology. 2021;74:1578-1594.
PubMed Abstract available

NIU Y, Lin Z, Wan A, Sun L, et al
Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
Hepatology. 2021;74:1461-1479.
PubMed Abstract available

STARLINGER P, Ahn JC, Mullan A, Gyoeri GP, et al
The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
Hepatology. 2021;74:1533-1545.
PubMed Abstract available

LAGO-HERNANDEZ C, Nguyen NH, Khera R, Loomba R, et al
Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States.
Hepatology. 2021;74:1509-1522.
PubMed Abstract available

LIU Y, Song J, Yang J, Zheng J, et al
Tumor Necrosis Factor alpha-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
Hepatology. 2021;74:1300-1318.
PubMed Abstract available

BEALS JW, Smith GI, Shankaran M, Fuchs A, et al
Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease.
Hepatology. 2021;74:1287-1299.
PubMed Abstract available

ANDREWS TS, MacParland SA
A Spotlight on the Drivers of Inflammation in Acute Liver Failure.
Hepatology. 2021;74:1687-1689.
PubMed

STRATAKIS N, Golden-Mason L, Margetaki K, Zhao Y, et al
In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.
Hepatology. 2021;74:1546-1559.
PubMed Abstract available

KUSUMANCHI P, Liang T, Zhang T, Ross RA, et al
Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling.
Hepatology. 2021;74:1234-1250.
PubMed Abstract available

WANG Y, Hylemon PB, Zhou H
Long Noncoding RNA H19: A Key Player in Liver Diseases.
Hepatology. 2021;74:1652-1659.
PubMed

August 2021

INNES H, Crooks CJ, Aspinall E, Card TR, et al
Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
PubMed Abstract available

VARGHESE J, Malleswaran S, Mouleeswaran K
Letter to the Editor: Toxin-induced Graft Injury following Liver Transplantation for Yellow Phosphorus Poisoning.
Hepatology. 2021 Aug 28. doi: 10.1002/hep.32124.
PubMed Abstract available

PLUMMER MD, Regenstein F
Light chain deposition disease: an unusual cause of portal hypertension.
Hepatology. 2021 Aug 27. doi: 10.1002/hep.32118.
PubMed Abstract available

FU J, Hu F, Ma T, Zhao WJ, et al
A conventional immune regulator MAVS blocks hepatic steatosis via maintaining mitochondrial homeostasis.
Hepatology. 2021 Aug 26. doi: 10.1002/hep.32126.
PubMed Abstract available

IMAI N, Nicholls HT, Alves-Bezerra M, Li Y, et al
Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.
Hepatology. 2021 Aug 25. doi: 10.1002/hep.32122.
PubMed Abstract available

LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
PubMed Abstract available

FAN S, Gao Y, Qu A, Jiang Y, et al
YAP-TEAD mediates peroxisome proliferator-activated receptor alpha-induced hepatomegaly and liver regeneration in mice.
Hepatology. 2021 Aug 13. doi: 10.1002/hep.32105.
PubMed Abstract available

FUCHS CD, Radun R, Dixon ED, Mlitz V, et al
Hepatocyte-specific deletion of adipose triglyceride lipase (ATGL/PNPLA2) ameliorates dietary induced steatohepatitis in mice.
Hepatology. 2021 Aug 13. doi: 10.1002/hep.32112.
PubMed Abstract available

EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
PubMed Abstract available

LIN Y, Cai Q, Chen Y, Shi T, et al
CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
PubMed Abstract available

WADHWANI SI, Ge J, Gottlieb L, Lyles C, et al
Racial/Ethnic Disparities in Wait List Outcomes Are Only Partly Explained by Socioeconomic Deprivation Among Children Awaiting Liver Transplantation.
Hepatology. 2021 Aug 13. doi: 10.1002/hep.32106.
PubMed Abstract available

ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
PubMed Abstract available

BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
PubMed Abstract available

WAHID N, Jesudian A, Buckholz A, Brown RS Jr, et al
Hepatology Highlights.
Hepatology. 2021;74:539-542.
PubMed

FIX OK, Blumberg EA, Chang KM, Chu J, et al
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.
Hepatology. 2021;74:1049-1064.
PubMed Abstract available

SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
Hepatology. 2021;74:1088-1100.
PubMed Abstract available

TROVATO FM, Zia R, Napoli S, Wolfer K, et al
Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
Hepatology. 2021;74:907-925.
PubMed Abstract available

CARTER J, Wang S, Friedman SL
Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.
Hepatology. 2021;74:543-546.
PubMed

FONTANA RJ, Stravitz RT, Durkalski V, Hanje J, et al
Prognostic Value of the (13) C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.
Hepatology. 2021;74:961-972.
PubMed Abstract available

REN H, Hu F, Wang D, Kang X, et al
Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4alpha.
Hepatology. 2021;74:723-740.
PubMed Abstract available

STRAVITZ RT, Fontana RJ, Meinzer C, Durkalski-Mauldin V, et al
Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.
Hepatology. 2021;74:937-949.
PubMed Abstract available

LEE D, Zhang MS, Tsang FH, Bao MH, et al
Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species.
Hepatology. 2021;74:776-796.
PubMed Abstract available

VEERAMACHANENI H, Subramanian RM
Combined High-Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure.
Hepatology. 2021;74:1124-1126.
PubMed

TRIANTOS C, Aggeletopoulou I, Thomopoulos K, Mouzaki A, et al
Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action.
Hepatology. 2021;74:1065-1073.
PubMed

July 2021

WIN S, Min RWM, Zhang J, Kanel G, et al
Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
PubMed Abstract available

ZHANG Z, Ji Z, He J, Lu Y, et al
GNAI2 exacerbates non-alcoholic steatohepatitis progression via regulating PRDX1-related inflammation and lipophagy.
Hepatology. 2021 Jul 29. doi: 10.1002/hep.32078.
PubMed Abstract available

SUDA T, Yoshikawa S, Kanefuji T, Abe S, et al
Suppression of Noncoding RNAs as Shared Early Genetic Events in Multistep Hepatocarcinogenesis.
Hepatology. 2021 Jul 29. doi: 10.1002/hep.32077.
PubMed Abstract available

MA L, Xu A, Kang L, Cong R, et al
LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.
Hepatology. 2021 Jul 29. doi: 10.1002/hep.32079.
PubMed Abstract available

LIU G, Wang N, Zhang C, Li M, et al
ALDOB depletion promotes hepatocellular carcinogenesis through activating insulin receptor signaling and lipogenesis.
Hepatology. 2021 Jul 22. doi: 10.1002/hep.32064.
PubMed Abstract available

MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
PubMed Abstract available

HU M, Zhang D, Xu H, Zhang Y, et al
Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis.
Hepatology. 2021 Jul 22. doi: 10.1002/hep.32066.
PubMed Abstract available

HE Q, Liu M, Huang W, Chen X, et al
IL-1beta-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.
Hepatology. 2021 Jul 20. doi: 10.1002/hep.32062.
PubMed Abstract available

YANG Q, Chen X, Zhang Y, Hu S, et al
The E3 ubiquitin ligase RNF5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of HRD1.
Hepatology. 2021 Jul 17. doi: 10.1002/hep.32061.
PubMed Abstract available

PIANO S, Cardenas A
Metabolomics to predict acute kidney injury in cirrhosis.
Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
PubMed Abstract available

MILLER BM, Oderberg IM, Goessling W
The Hepatic Nervous System in Development, Regeneration, and Disease.
Hepatology. 2021 Jul 13. doi: 10.1002/hep.32055.
PubMed Abstract available

ZHENG J, Daniel CR, Hatia RI, Stuff J, et al
Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study.
Hepatology. 2021 Jul 7. doi: 10.1002/hep.32046.
PubMed Abstract available

LAI JC, Tandon P, Bernal W, Tapper EB, et al
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
PubMed Abstract available

KIM OK, Nam DE, Hahn YS
The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
PubMed Abstract available

CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
PubMed Abstract available

BUCKHOLZ A, Lucero C, Yang LM, Lau DTY, et al
Hepatology Highlights.
Hepatology. 2021;74:1-4.
PubMed

WILSON A, Beaton M, Brahmania M
Letter to the Editor: Nonalcoholic Fatty Liver Disease-One Size May Not Fit All.
Hepatology. 2021;74:528.
PubMed

DIENSTAG JL
Introducing Raymond T. Chung, M.D., Our 2021 AASLD President.
Hepatology. 2021;74:12-18.
PubMed

SZABO G
Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD.
Hepatology. 2021;74:5-8.
PubMed

PARTHASARATHY G, Malhi H
Macrophage Heterogeneity in NASH: More Than Just Nomenclature.
Hepatology. 2021;74:515-518.
PubMed

NOUREDDIN M
Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans.
Hepatology. 2021;74:9-11.
PubMed

HUANG Z, Chu L, Liang J, Tan X, et al
H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.
Hepatology. 2021;74:214-232.
PubMed Abstract available

TAYLOR-WEINER A, Pokkalla H, Han L, Jia C, et al
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
Hepatology. 2021;74:133-147.
PubMed Abstract available

COPPLE IM, Park BK, Goldring CE
Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening.
Hepatology. 2021;74:513-515.
PubMed

HAGSTROM H, Adams LA, Allen AM, Byrne CD, et al
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.
Hepatology. 2021;74:474-482.
PubMed Abstract available

HE Y, Shi M, Wu X, Ma J, et al
Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer.
Hepatology. 2021;74:264-280.
PubMed Abstract available

KENNEDY L, Meadows V, Sybenga A, Demieville J, et al
Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
Hepatology. 2021;74:164-182.
PubMed Abstract available

WANG H, Song X, Liao H, Wang P, et al
Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
Hepatology. 2021;74:248-263.
PubMed Abstract available

JIANG T, Sanchez-Rivera FJ, Soto-Feliciano YM, Yang Q, et al
Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.
Hepatology. 2021;74:233-247.
PubMed Abstract available

GOUDSMIT BFJ, Putter H, Tushuizen ME, Vogelaar S, et al
Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.
Hepatology. 2021;74:351-363.
PubMed Abstract available

BERNARDO-SEISDEDOS G, Bilbao J, Fernandez-Ramos D, Lopitz-Otsoa F, et al
Metabolic Landscape of the Mouse Liver by Quantitative (31) P Nuclear Magnetic Resonance Analysis of the Phosphorome.
Hepatology. 2021;74:148-163.
PubMed Abstract available

HOU X, Yin S, Ren R, Liu S, et al
Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
Hepatology. 2021;74:116-132.
PubMed Abstract available

WOOD NL, Kernodle AB, Hartley AJ, Segev DL, et al
Heterogeneous Circles for Liver Allocation.
Hepatology. 2021;74:312-321.
PubMed Abstract available

POSE E, Coll M, Martinez-Sanchez C, Zeng Z, et al
Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
Hepatology. 2021;74:296-311.
PubMed Abstract available

June 2021

FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
PubMed Abstract available

GARATE-RASCON M, Recalde M, Jimenez M, Elizalde M, et al
SLU7 prevents oxidative stress-mediated HNF4alpha degradation preserving hepatic differentiation and protecting from liver damage.
Hepatology. 2021 Jun 25. doi: 10.1002/hep.32029.
PubMed Abstract available

HIRAO H, Ito T, Kadono K, Kojima H, et al
Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
PubMed Abstract available

KRIEGERMEIER A, Hyon A, Sommars M, Hubchak S, et al
Hepatic X-box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury.
Hepatology. 2021 Jun 25. doi: 10.1002/hep.32031.
PubMed Abstract available

CHOLANKERIL G, Kanwal F
Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap.
Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025.
PubMed Abstract available

TORRENS L, Montironi C, Puigvehi M, Mesropian A, et al
Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.
Hepatology. 2021 Jun 22. doi: 10.1002/hep.32023.
PubMed Abstract available

LIU H, Lee SS
Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
PubMed Abstract available

JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
PubMed Abstract available

SHI YF, Xie WZ
Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
PubMed Abstract available

MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
PubMed Abstract available

BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
PubMed Abstract available

LEE YT, Wang JJ, Luu M, Noureddin M, et al
Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
PubMed Abstract available

JINDAL A, Sharma S
Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
PubMed Abstract available

SOLIPURAM V, Baretti M, Kim AY, Chen LX, et al
Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
Hepatology. 2021 Jun 9. doi: 10.1002/hep.31998.
PubMed Abstract available

SHAH V, Iwakiri Y, Boyer JL
Obituary for Roberto J. Groszmann - the Father of Portal Hypertension.
Hepatology. 2021 Jun 9. doi: 10.1002/hep.31996.
PubMed Abstract available

KOZUMI K, Kodama T, Murai H, Sakane S, et al
Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
PubMed Abstract available

CHO K, Ro SW, Lee HW, Moon H, et al
YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation.
Hepatology. 2021 Jun 8. doi: 10.1002/hep.32000.
PubMed Abstract available

CHEN B, Wu JX, Cheng SH, Wang LM, et al
Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma.
Hepatology. 2021 Jun 7. doi: 10.1002/hep.31993.
PubMed Abstract available

JINDAL A, Jagdish RK
Response to terlipressin plus albumin in Hepatorenal syndrome - Need a closer look!
Hepatology. 2021 Jun 6. doi: 10.1002/hep.31990.
PubMed Abstract available

WONG TC, Lee VH, Law AL, Pang HH, et al
Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
Hepatology. 2021 Jun 6. doi: 10.1002/hep.31992.
PubMed Abstract available

YANG W, He H, Wang T, Su N, et al
Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
PubMed Abstract available

MUHAMMAD KHAN M, Alejandra Luna-Cuadros M, Lau DTY, Sehrawat TS, et al
Hepatology Highlights.
Hepatology. 2021;73:2085-2088.
PubMed

ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
PubMed Abstract available

KULKARNI AV, Kumar P, Sharma M, Menon B, et al
Letter to the Editor: Living Donor Liver Transplantation or Deceased Donor Liver Transplantation in High Model for End-Stage Liver Disease Score-Which Is Better?
Hepatology. 2021;73:2619-2620.
PubMed

VUPPALANCHI R, Loomba R
Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.
Hepatology. 2021;73:2095-2098.
PubMed

CASSINOTTO C, Boursier J, Paisant A, Guiu B, et al
Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
Hepatology. 2021;73:2196-2205.
PubMed Abstract available

LIN Q, Huang Z, Cai G, Fan X, et al
Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
Hepatology. 2021;73:2206-2222.
PubMed Abstract available

KENNEDY L, Francis H, Alpini G
Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn't So Sweet.
Hepatology. 2021;73:2092-2094.
PubMed

CHO YE, Kim DK, Seo W, Gao B, et al
Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress.
Hepatology. 2021;73:2180-2195.
PubMed Abstract available

MARTINS PN, Clavien PA, Jalan R, Ghinolfi D, et al
A Call for Randomization in Clinical Trials of Liver Machine Perfusion Preservation.
Hepatology. 2021;73:2586-2591.
PubMed

MOON JH, Stormon MO
Sucrose Toxicity in Infants.
Hepatology. 2021;73:2607-2609.
PubMed

AHN JC, Connell A, Simonetto DA, Hughes C, et al
Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases.
Hepatology. 2021;73:2546-2563.
PubMed Abstract available

HOOFNAGLE JH, Bonkovsky HL, Phillips EJ, Li YJ, et al
HLA-B*35:01 and Green Tea-Induced Liver Injury.
Hepatology. 2021;73:2484-2493.
PubMed Abstract available

KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
Hepatology. 2021;73:2397-2410.
PubMed Abstract available

May 2021

VIVEIROS A, Schaefer B, Panzer M, Henninger B, et al
MRI-based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of non-HFE Hemochromatosis Genes.
Hepatology. 2021 May 28. doi: 10.1002/hep.31982.
PubMed Abstract available

LEPORE A, Choy PM, Lee NC, Carella MA, et al
Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
PubMed Abstract available

JOHNSTON ME 2ND, Rivas MP, Nicolle D, Gorse A, et al
Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient Derived Xenograft Models.
Hepatology. 2021 May 26. doi: 10.1002/hep.31919.
PubMed Abstract available

YI C, Chen L, Ling Z, Liu L, et al
Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.
Hepatology. 2021 May 26. doi: 10.1002/hep.31921.
PubMed Abstract available

SUN LY, Hu JY, Liang L, Tong XM, et al
Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
PubMed Abstract available

JOHN BV, Deng Y, Martin P, Levy C, et al
Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
PubMed Abstract available

MEHTA G, Jalan R
The 'Alter Ego' of Albumin in Cirrhosis.
Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
PubMed Abstract available

BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
PubMed Abstract available

JANSSON H, Sparrelid E
Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
PubMed Abstract available

MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
PubMed Abstract available

LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
PubMed Abstract available

PEISELER M, Tacke F
An unexpected line of defense: hepatoprotective eosinophils in ischemia-reperfusion injury.
Hepatology. 2021 May 11. doi: 10.1002/hep.31895.
PubMed Abstract available

VALSAN A, Verma N, Singh V
Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
PubMed Abstract available

ELKRIEF L, Lazareth M, Rautou PE
Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
PubMed Abstract available

DICHTEL LE
The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
PubMed Abstract available

BIGGINS SW, Angeli P, Garcia-Tsao G, Gines P, et al
Diagnosis, evaluation, and management of ascites and hepatorenal syndrome.
Hepatology. 2021 May 3. doi: 10.1002/hep.31884.
PubMed Abstract available

LIU Y, Dou X, Zhou WY, Ding M, et al
Hepatic SENP2 Controls Systemic Metabolism via SUMOylation-dependent Regulation of Liver-Adipose Tissue Crosstalk.
Hepatology. 2021 May 2. doi: 10.1002/hep.31881.
PubMed Abstract available

BUCKHOLZ A, Jesudian A, Sehrawat TS, Sehrawat O, et al
Hepatology Highlights.
Hepatology. 2021;73:1627-1630.
PubMed

Seeking Editor for Hepatology Communications.
Hepatology. 2021;73:i.
PubMed

LEI MML, Lee TKW
Cancer-Associated Fibroblasts: Orchestrating the Crosstalk Between Liver Cancer Cells and Neutrophils Through the Cardiotrophin-Like Cytokine Factor 1-Mediated Chemokine (C-X-C motif) Ligand 6/TGF-beta Axis.
Hepatology. 2021;73:1631-1633.
PubMed

LEE WM, Kaplowitz N
Alcohol, Fasting, and Therapeutic Dosing of Acetaminophen: A Perfect Storm.
Hepatology. 2021;73:1634-1636.
PubMed

LOUVET A, Ntandja Wandji LC, Lemaitre E, Khaldi M, et al
Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study.
Hepatology. 2021;73:1945-1955.
PubMed Abstract available

ASRANI SK, Mellinger J, Arab JP, Shah VH, et al
Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action.
Hepatology. 2021;73:2039-2050.
PubMed Abstract available

SUNDARAM V, Jalan R, Shah P, Singal AK, et al
Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality.
Hepatology. 2021;73:1932-1944.
PubMed Abstract available

HAFNER S, Seufferlein T, Kleger A, Muller M, et al
Aseptic Liver Abscesses as an Exceptional Finding in Cogan's Syndrome.
Hepatology. 2021;73:2067-2070.
PubMed

LI Z, Lu X, Liu Y, Zhao J, et al
Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex.
Hepatology. 2021;73:1764-1782.
PubMed Abstract available

DAVULURI G, Welch N, Sekar J, Gangadhariah M, et al
Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease.
Hepatology. 2021;73:1892-1908.
PubMed Abstract available

MA Y, Brown PM, Lin DD, Ma J, et al
17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
Hepatology. 2021;73:1701-1716.
PubMed Abstract available

DRIEVER EG, Stravitz RT, Zhang J, Adelmeijer J, et al
VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.
Hepatology. 2021;73:1882-1891.
PubMed Abstract available

April 2021

SHENG J, Kohno S, Okada N, Okahashi N, et al
Treatment of RB1-intact hepatocellular carcinoma with CDK4/6 inhibitor combination therapy.
Hepatology. 2021 Apr 30. doi: 10.1002/hep.31872.
PubMed Abstract available

BUCKARMA E, Smoot R
Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.
Hepatology. 2021 Apr 30. doi: 10.1002/hep.31874.
PubMed Abstract available

ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
PubMed Abstract available

LUO Y, Gao Y, Liu W, Yang Y, et al
MYC-Protein Arginine Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864.
PubMed Abstract available

YANG X, Sun D, Xiang H, Wang S, et al
Hepatocyte SH3RF2 Deficiency is a Key Aggravator for Nonalcoholic Fatty Liver Disease.
Hepatology. 2021 Apr 24. doi: 10.1002/hep.31863.
PubMed Abstract available

LIU D, Pang J, Shao W, Gu J, et al
Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge.
Hepatology. 2021 Apr 13. doi: 10.1002/hep.31856.
PubMed Abstract available

XU X, Ye L, Zhang Q, Shen H, et al
Group-2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2-Neutrophil Induced Immunosuppression.
Hepatology. 2021 Apr 8. doi: 10.1002/hep.31855.
PubMed Abstract available

SUN D, Yang X, Wu B, Zhang XJ, et al
Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis.
Hepatology. 2021 Apr 7. doi: 10.1002/hep.31852.
PubMed Abstract available

WING-SUM CHEU J, Chak-Lui Wong C
Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors.
Hepatology. 2021 Apr 3. doi: 10.1002/hep.31840.
PubMed Abstract available

KOVALIC AJ, Huang G, Thuluvath PJ, Satapathy SK, et al
Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.
Hepatology. 2021;73:1521-1530.
PubMed Abstract available

FU Y, Zhu R, Bai T, Han P, et al
Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
Hepatology. 2021;73:1509-1520.
PubMed Abstract available

KAUR SP, Trivedi H, Lau DTY, Bamidele AO, et al
Hepatology Highlights.
Hepatology. 2021;73:1245-1247.
PubMed

Seeking Editor for Hepatology Communications.
Hepatology. 2021;73:i.
PubMed

DE ZEGHER F, Ibanez L
Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
Hepatology. 2021;73:1623-1624.
PubMed

GOLRIZ M, Ramouz A, Mehrabi A
Letter to the Editor: Surgical Method for Establishing Posthepatectomy Liver Failure.
Hepatology. 2021;73:1621.
PubMed

DHAR D, Loomba R
Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH.
Hepatology. 2021;73:1248-1250.
PubMed

XU H, Tian Y, Tang D, Zou S, et al
An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.
Hepatology. 2021;73:1327-1345.
PubMed Abstract available

SONG Z, Chen W, Athavale D, Ge X, et al
Osteopontin Takes Center Stage in Chronic Liver Disease.
Hepatology. 2021;73:1594-1608.
PubMed Abstract available

ALKHOURI N, Reddy GK, Lawitz E
Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.
Hepatology. 2021;73:1581-1593.
PubMed

ARJUNAN V, Hansen A, Deutzmann A, Sze DY, et al
Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer.
Hepatology. 2021;73:1611-1614.
PubMed

OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Hepatology. 2021;73:1399-1418.
PubMed Abstract available

CHEN L, Guo P, Li W, Fang F, et al
Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
Hepatology. 2021;73:1551-1569.
PubMed Abstract available

March 2021

ROSENBLATT R, Wahid N, Halazun KJ, Kaplan A, et al
Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States.
Hepatology. 2021 Mar 29. doi: 10.1002/hep.31837.
PubMed Abstract available

DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
PubMed Abstract available

CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
PubMed Abstract available

KENDRE G, Marhenke S, Lorz G, Becker D, et al
The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
PubMed Abstract available

VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
PubMed Abstract available

VANDERWERKEN D, Wood NL, Segev D, Gentry S, et al
The Precise Relationship Between MELD and Survival Without a Liver Transplant.
Hepatology. 2021 Mar 2. doi: 10.1002/hep.31781.
PubMed Abstract available

ZHOU Y, Chen Y, Zhang X, Xu Q, et al
Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
PubMed Abstract available

MCHENRY SA, Davidson NO
Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH.
Hepatology. 2021;73:884-886.
PubMed

MELLINGER J, Winder GS, Fernandez AC
Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research.
Hepatology. 2021;73:1207-1212.
PubMed

WEGERMANN K, Suzuki A, Mavis AM, Abdelmalek MF, et al
Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.
Hepatology. 2021;73:1199-1206.
PubMed

PAPAROUPA M, Schrader J, Jung C, Boenisch O, et al
Bilateral Hematothorax Without Hematemesis-An Unusual Presentation of Variceal Bleeding.
Hepatology. 2021;73:1233-1235.
PubMed

GODBEE M, Jakate S, Eswaran S
A Case of Electronic Nicotine Delivery Systems (ENDS) Liver Injury.
Hepatology. 2021;73:1230-1232.
PubMed

YOUNOSSI ZM, Rinella ME, Sanyal AJ, Harrison SA, et al
From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
Hepatology. 2021;73:1194-1198.
PubMed Abstract available

PROTCHENKO O, Baratz E, Jadhav S, Li F, et al
Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis.
Hepatology. 2021;73:1176-1193.
PubMed Abstract available

February 2021

HERCUN J, Parikh E, Kleiner DE, Fuss I, et al
Recurrent nodular regenerative hyperplasia post-liver transplantation in common variable immunodeficiency.
Hepatology. 2021 Feb 27. doi: 10.1002/hep.31775.
PubMed Abstract available

MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
PubMed Abstract available

NASSER-GHODSI N, Mara K, Watt KD
De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
PubMed Abstract available

DI GUGLIELMO MD, Perito ER
To Juice or Not to Juice: Fatty Liver Repercussions for Infants.
Hepatology. 2021;73:483-485.
PubMed

PIROLA CJ, Sookoian S
NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
Hepatology. 2021;73:479-482.
PubMed

GEURTSEN ML, Santos S, Gaillard R, Felix JF, et al
Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age.
Hepatology. 2021;73:560-570.
PubMed Abstract available

TILG H, Adolph TE, Moschen AR
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.
Hepatology. 2021;73:833-842.
PubMed

AL-NAAMANI N, Krowka MJ, Forde KA, Krok KL, et al
Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
Hepatology. 2021;73:726-737.
PubMed Abstract available

JUNG YS, Stratton SA, Lee SH, Kim MJ, et al
TMEM9-v-ATPase Activates Wnt/beta-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis.
Hepatology. 2021;73:776-794.
PubMed Abstract available

HU W, Zheng S, Guo H, Dai B, et al
PLAGL2-EGFR-HIF-1/2alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
Hepatology. 2021;73:674-691.
PubMed Abstract available

ZUO Q, He J, Zhang S, Wang H, et al
PPARgamma Coactivator-1alpha Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARgamma-Dependent WNT/beta-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
Hepatology. 2021;73:644-660.
PubMed Abstract available

January 2021

ITOH A, Adams D, Huang W, Wu Y, et al
Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
PubMed Abstract available

JAESCHKE H, Ramachandran A
Letter to the Editor: Does c-Jun N-Terminal Kinase Regulate Acetaminophen Hepatotoxicity by Modulating Nuclear Factor Erythroid 2-Related Factor 2-Dependent Genes or Mitochondrial Oxidant Stress?
Hepatology. 2021;73:467-468.
PubMed

TANG X, Wang XJ
REPLY.
Hepatology. 2021;73:468-469.
PubMed

CHOI J, Lim YS
REPLY.
Hepatology. 2021;73:467.
PubMed

CASEY L, Aday A, Rule J, Lee WM, et al
Letter to the Editor: Response to Letter Concerning Our Pregnancy Manuscript.
Hepatology. 2021;73:465.
PubMed

NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
Hepatology. 2021;73:366-413.
PubMed

SARKAR M, Brady CW, Fleckenstein J, Forde KA, et al
Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.
Hepatology. 2021;73:318-365.
PubMed

DE JONGHE S, Weinstock D, Aligo J, Washington K, et al
Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat.
Hepatology. 2021;73:452-455.
PubMed

LEONIS MA, Miethke AG, Fei L, Maynor S, et al
Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.
Hepatology. 2021;73:233-246.
PubMed Abstract available

LI YJ, Phillips EJ, Dellinger A, Nicoletti P, et al
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
Hepatology. 2021;73:268-281.
PubMed Abstract available

MORENO E, Toussaint MJM, van Essen SC, Bongiovanni L, et al
E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
Hepatology. 2021;73:303-317.
PubMed Abstract available

GU L, Zhu Y, Lin X, Lu B, et al
The IKKbeta-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.
Hepatology. 2021;73:160-174.
PubMed Abstract available

ZHOU B, Liu C, Xu L, Yuan Y, et al
N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes.
Hepatology. 2021;73:91-103.
PubMed Abstract available

CABALLERO-CAMINO FJ, Rivilla I, Herraez E, Briz O, et al
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
Hepatology. 2021;73:186-203.
PubMed Abstract available

FENG GS, Hanley KL, Liang Y, Lin X, et al
Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
Hepatology. 2021;73 Suppl 1:104-114.
PubMed Abstract available

RIZVI S, Wang J, El-Khoueiry AB
Liver Cancer Immunity.
Hepatology. 2021;73 Suppl 1:86-103.
PubMed

CARUSO S, O'Brien DR, Cleary SP, Roberts LR, et al
Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity.
Hepatology. 2021;73 Suppl 1:14-26.
PubMed

LU X, Paliogiannis P, Calvisi DF, Chen X, et al
Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
Hepatology. 2021;73 Suppl 1:49-61.
PubMed Abstract available

PEA A, Jamieson NB, Braconi C
Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma.
Hepatology. 2021;73 Suppl 1:38-48.
PubMed Abstract available

December 2020

NOUREDDIN N, Alkhouri N, Brown KA, Noureddin M, et al
Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
Hepatology. 2020;72:2228-2230.
PubMed

MEHTA N, Yao FY
Reply.
Hepatology. 2020;72:2243-2244.
PubMed

SELCK TJ, Bok J, Amintavakoli R
Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
Hepatology. 2020;72:2239.
PubMed

VENTURA-COTS M, Abraldes JG, Bataller R
Reply.
Hepatology. 2020;72:2239-2240.
PubMed

November 2020

KWON HM, Moon YJ, Kim KS, Shin WJ, et al
Prognostic value of B-type natriuretic peptide in liver transplant patients: Implication in post-transplant mortality.
Hepatology. 2020 Nov 28. doi: 10.1002/hep.31661.
PubMed Abstract available

BARMAN PM, VanWagner LB
Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.
Hepatology. 2020 Nov 20. doi: 10.1002/hep.31647.
PubMed Abstract available

LOUSTAUD-RATTI V, Anneraud A, Carrier P, Debette-Gratien M, et al
Letter to the Editor: Post-Liver Transplantation Sinusoidal Obstruction Syndrome and immunosuppressive drugs: causality of MMF or tacrolimus?
Hepatology. 2020 Nov 13. doi: 10.1002/hep.31633.
PubMed Abstract available

SMETS L, Verbeek J, Korf H, van der Merwe S, et al
Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
PubMed Abstract available

CAVE MC
Environmental Pollution and the Developmental Origins of Childhood Liver Disease.
Hepatology. 2020;72:1518-1521.
PubMed

JAESCHKE H, Ramachandran A
Pleiotropic Roles of Platelets and Neutrophils in Cell Death and Recovery During Acetaminophen Hepatotoxicity.
Hepatology. 2020;72:1873-1876.
PubMed

SINGH S, Verma N, Singh V
Letter to the Editor: MELD-Lactate-the New Kid on the Block.
Hepatology. 2020;72:1883.
PubMed

October 2020

ANTKOWIAK M, Green RM
Telomeres, p53, Hepatocyte Nuclear Factor 4alpha, and Liver Disease.
Hepatology. 2020;72:1166-1168.
PubMed

LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
Reply.
Hepatology. 2020;72:1494-1495.
PubMed

KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
Hepatology. 2020;72:1310-1326.
PubMed Abstract available

September 2020

JASPER S, Hakeem AR, Vij M, Sachan D, et al
First report of toxin-induced graft injury following liver transplantation for Yellow Phosphorus Poisoning.
Hepatology. 2020 Sep 16. doi: 10.1002/hep.31553.
PubMed Abstract available

CHEN L, Zhou T, White T, O'Brien A, et al
The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
PubMed Abstract available

JIANG X, Ding WX
Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids?
Hepatology. 2020;72:797-800.
PubMed

GUICCIARDI ME, Nakao Y, Gores GJ
The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis.
Hepatology. 2020;72:1139-1141.
PubMed

KUMAR M
Reply.
Hepatology. 2020;72:1160.
PubMed

WEISS TS, Melter M, Dayoub R
Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression?
Hepatology. 2020;72:1156-1157.
PubMed

VERMA AK, Gandhi CR
Reply.
Hepatology. 2020;72:1157-1158.
PubMed

August 2020

FRISSEN M, Liao L, Schneider KM, Djudjaj S, et al
Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury.
Hepatology. 2020 Aug 4. doi: 10.1002/hep.31494.
PubMed Abstract available

WEN Y, Ju C
MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
Hepatology. 2020;72:772-774.
PubMed

SINHA RA, Bruinstroop E, Singh BK, Yen PM, et al
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
Hepatology. 2020;72:770-771.
PubMed

GAWRIEH S, Kleiner DE, Chalasani N, Vanderbeck S, et al
Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease.
Hepatology. 2020;72:785.
PubMed

WEI L, Chang PEJ, Anstee QM
Reply.
Hepatology. 2020;72:786.
PubMed

KWON HM, Hwang GS
Reply.
Hepatology. 2020;72:784.
PubMed

HUANG JF, Dai CY, Yu ML, Chuang WL, et al
Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
Hepatology. 2020;72:781.
PubMed

July 2020

AMZAL R, Thebaut A, Lapalus M, Almes M, et al
Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
PubMed Abstract available

WANG Y
Letter to the Editor: Issues of Circular RNAs as MicroRNA Sponges.
Hepatology. 2020;72:365.
PubMed

LI L, Wei Y, Wang H
REPLY.
Hepatology. 2020;72:366.
PubMed

HOOFNAGLE JH
FXR Agonists as Therapy for Liver Disease.
Hepatology. 2020;72:1-3.
PubMed

MALLAT A, Lotersztajn S
Glutamate Signaling in Alcohol-associated Fatty Liver: "Pas de Deux".
Hepatology. 2020;72:350-352.
PubMed

SU T, Iwakiri Y
Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
Hepatology. 2020;72:347-349.
PubMed

YANG JD, Mara KC, Gores GJ, Roberts LR, et al
Reply.
Hepatology. 2020;72:364-365.
PubMed

YANG JD, Mara KC, Gores GJ, Roberts LR, et al
REPLY.
Hepatology. 2020;72:362-363.
PubMed

ARASE Y, Kagawa T, Tanaka A
Reply.
Hepatology. 2020;72:360-361.
PubMed

LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
Hepatology. 2020;72:359-360.
PubMed

June 2020

ABUD A, Maddur H, Salem R
Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
PubMed Abstract available

KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
PubMed Abstract available

THALJI L, Thalji NM, Heimbach JK, Ibrahim SH, et al
Renal Function Parameters and Serum Sodium Enhance Prediction of Waitlist Outcomes in Pediatric Liver Transplantation.
Hepatology. 2020 Jun 2. doi: 10.1002/hep.31397.
PubMed Abstract available

LUCEY MR, Singal AK
Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
Hepatology. 2020;71:1891-1893.
PubMed

May 2020

GABR A, Kulik L, Mouli S, Riaz A, et al
Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort.
Hepatology. 2020 May 16. doi: 10.1002/hep.31318.
PubMed Abstract available

ZHOU J, Zhou F, Wang W, Zhang XJ, et al
Epidemiological Features of NAFLD From 1999 to 2018 in China.
Hepatology. 2020;71:1851-1864.
PubMed Abstract available

CHEN Y, Liu K, Zhang J, Hai Y, et al
c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.
Hepatology. 2020;71:1787-1801.
PubMed Abstract available

GAO W, Jia Z, Tian Y, Yang P, et al
HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
Hepatology. 2020;71:1678-1695.
PubMed Abstract available

FLEMING BD, Urban DJ, Hall MD, Longerich T, et al
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Hepatology. 2020;71:1696-1711.
PubMed Abstract available

XIE C, Zhang LZ, Chen ZL, Zhong WJ, et al
A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
Hepatology. 2020;71:1660-1677.
PubMed Abstract available

April 2020

KHALAF RT, Sokol RJ
New Insights Into Intestinal Failure-Associated Liver Disease in Children.
Hepatology. 2020;71:1486-1498.
PubMed Abstract available

XIONG X, Kuang H, Liu T, Lin JD, et al
A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
Hepatology. 2020;71:1467-1473.
PubMed

IBRAHIM SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, et al
Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.
Hepatology. 2020;71:1474-1485.
PubMed Abstract available

XIONG J, Liu T, Mi L, Kuang H, et al
hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis.
Hepatology. 2020;71:1228-1246.
PubMed Abstract available

LIU J, Wu Z, Han D, Wei C, et al
Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-kappaB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
Hepatology. 2020;71:1262-1278.
PubMed Abstract available

ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
Hepatology. 2020;71:1331-1349.
PubMed Abstract available

CHEN F, Esmaili S, Rogers GB, Bugianesi E, et al
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
Hepatology. 2020;71:1213-1227.
PubMed Abstract available

ZHANG C, Lin R, Li Z, Yang S, et al
Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
Hepatology. 2020;71:1297-1315.
PubMed Abstract available

SHIGETA K, Datta M, Hato T, Kitahara S, et al
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Hepatology. 2020;71:1247-1261.
PubMed Abstract available

March 2020

SCHWACHA-EIPPER B, Minciuna I, Banz V, Dufour JF, et al
Immunotherapy as a downstaging therapy for liver transplantation.
Hepatology. 2020 Mar 14. doi: 10.1002/hep.31234.
PubMed Abstract available

ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
PubMed Abstract available

February 2020

NAULT JC, Villanueva A
Biomarkers for hepatobiliary cancers.
Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
PubMed Abstract available

DEROO R, Trepo E, Holvoet T, De Pauw M, et al
Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.
Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164.
PubMed Abstract available

January 2020

WALLACE D, Cowling T, PcPhail MJ, Brown SE, et al
Assessing the time-dependent impact of performance status on outcomes after liver transplantation.
Hepatology. 2020 Jan 22. doi: 10.1002/hep.31124.
PubMed Abstract available

December 2019

GAO E, Cheema H, Waheed N, Mushtaq I, et al
OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
PubMed Abstract available

November 2019

GYORI GP, Pereyra D, Rumpf B, Hackl H, et al
Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
Hepatology. 2019 Nov 27. doi: 10.1002/hep.31047.
PubMed Abstract available

LEE BP, Vittinghoff E, Pletcher MJ, Dodge JL, et al
Medicaid Policy and Liver Transplant for Alcohol-Related Liver Disease.
Hepatology. 2019 Nov 8. doi: 10.1002/hep.31027.
PubMed Abstract available

KUTKUT I, Rachwan RJ, Timsina LR, Ghabril MS, et al
Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality.
Hepatology. 2019 Nov 7. doi: 10.1002/hep.31023.
PubMed Abstract available

EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
PubMed Abstract available

October 2019

POLI E, Kounis I, Guettier C, Verstuyft C, et al
Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
PubMed Abstract available

SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
PubMed Abstract available

September 2019

KIM YC, Jung H, Seok S, Zhang Y, et al
MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
PubMed Abstract available

DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
PubMed Abstract available

ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
PubMed Abstract available

TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
PubMed Abstract available

August 2019

KWON HM, Moon YJ, Jung KW, Park YS, et al
Appraisal of cardiac ejection fraction with liver disease severity: Implication in post-liver transplantation mortality.
Hepatology. 2019 Aug 28. doi: 10.1002/hep.30913.
PubMed Abstract available

MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.